drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
listlengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00023 | DB04896 | 305 | 901 | [
"DDInter127",
"DDInter1220"
] | Asparaginase Escherichia coli | Milnacipran | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible proposal that noradrenaline plays an important role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. Moreover, recent research has shown that the levorotatory enantiomer of milnacipran, levomilnacipran, may have the capacity to inhibit the activity of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease . | Moderate | 1 | [
[
[
305,
24,
901
]
],
[
[
305,
24,
256
],
[
256,
63,
901
]
],
[
[
305,
24,
500
],
[
500,
24,
901
]
],
[
[
305,
25,
1510
],
[
1510,
64,
901
]
],
[
[
305,
25,
1377
],
[
1377,
25,
901
]
],
[
[
305,
24,
593
],
[
593,
25,
901
]
],
[
[
305,
24,
256
],
[
256,
24,
41
],
[
41,
1,
901
]
],
[
[
305,
24,
850
],
[
850,
24,
292
],
[
292,
63,
901
]
],
[
[
305,
24,
482
],
[
482,
21,
28722
],
[
28722,
60,
901
]
],
[
[
305,
24,
1421
],
[
1421,
63,
41
],
[
41,
1,
901
]
]
] | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Milnacipran"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Milnacipran"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Milnacipran"
]
]
] | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Milnacipran
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Milnacipran
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Milnacipran
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Milnacipran (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound) |
DB08889 | DB08894 | 350 | 1,126 | [
"DDInter299",
"DDInter1406"
] | Carfilzomib | Peginesatide | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy. | Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012. | Major | 2 | [
[
[
350,
25,
1126
]
],
[
[
350,
64,
1514
],
[
1514,
24,
1126
]
],
[
[
350,
25,
687
],
[
687,
63,
1126
]
],
[
[
350,
63,
770
],
[
770,
25,
1126
]
],
[
[
350,
64,
1514
],
[
1514,
64,
770
],
[
770,
25,
1126
]
],
[
[
350,
25,
687
],
[
687,
64,
770
],
[
770,
25,
1126
]
],
[
[
350,
6,
4973
],
[
4973,
45,
610
],
[
610,
23,
1126
]
],
[
[
350,
63,
770
],
[
770,
25,
1514
],
[
1514,
24,
1126
]
],
[
[
350,
21,
28850
],
[
28850,
60,
610
],
[
610,
23,
1126
]
],
[
[
350,
63,
770
],
[
770,
25,
687
],
[
687,
63,
1126
]
]
] | [
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginesatide"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human C1-esterase inhibitor"
],
[
"Human C1-esterase inhibitor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginesatide"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conestat alfa"
],
[
"Conestat alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginesatide"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginesatide"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human C1-esterase inhibitor"
],
[
"Human C1-esterase inhibitor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginesatide"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conestat alfa"
],
[
"Conestat alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginesatide"
]
],
[
[
"Carfilzomib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Peginesatide"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human C1-esterase inhibitor"
],
[
"Human C1-esterase inhibitor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginesatide"
]
],
[
[
"Carfilzomib",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Peginesatide"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conestat alfa"
],
[
"Conestat alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginesatide"
]
]
] | Carfilzomib may lead to a major life threatening interaction when taken with Human C1-esterase inhibitor and Human C1-esterase inhibitor may cause a moderate interaction that could exacerbate diseases when taken with Peginesatide
Carfilzomib may lead to a major life threatening interaction when taken with Conestat alfa and Conestat alfa may cause a moderate interaction that could exacerbate diseases when taken with Peginesatide
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Peginesatide
Carfilzomib may lead to a major life threatening interaction when taken with Human C1-esterase inhibitor and Human C1-esterase inhibitor may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Peginesatide
Carfilzomib may lead to a major life threatening interaction when taken with Conestat alfa and Conestat alfa may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Peginesatide
Carfilzomib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Enalapril (Compound) and Enalapril may cause a minor interaction that can limit clinical effects when taken with Peginesatide
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Human C1-esterase inhibitor and Human C1-esterase inhibitor may cause a moderate interaction that could exacerbate diseases when taken with Peginesatide
Carfilzomib (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Enalapril (Compound) and Enalapril may cause a minor interaction that can limit clinical effects when taken with Peginesatide
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Conestat alfa and Conestat alfa may cause a moderate interaction that could exacerbate diseases when taken with Peginesatide |
DB06704 | DB11601 | 247 | 1,270 | [
"DDInter952",
"DDInter1889"
] | Iobenguane (I-131) | Tuberculin purified protein derivative | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
247,
24,
1270
]
],
[
[
247,
63,
820
],
[
820,
24,
1270
]
],
[
[
247,
63,
820
],
[
820,
63,
1555
],
[
1555,
24,
1270
]
],
[
[
247,
6,
7390
],
[
7390,
45,
272
],
[
272,
24,
1270
]
],
[
[
247,
7,
6952
],
[
6952,
46,
77
],
[
77,
24,
1270
]
],
[
[
247,
63,
820
],
[
820,
24,
1250
],
[
1250,
24,
1270
]
],
[
[
247,
18,
7359
],
[
7359,
57,
147
],
[
147,
24,
1270
]
],
[
[
247,
18,
9226
],
[
9226,
46,
869
],
[
869,
24,
1270
]
],
[
[
247,
63,
820
],
[
820,
25,
985
],
[
985,
24,
1270
]
],
[
[
247,
21,
28787
],
[
28787,
60,
1573
],
[
1573,
24,
1270
]
]
] | [
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Iobenguane",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Iobenguane",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Iobenguane",
"{u} (Compound) downregulates {v} (Gene)",
"TXNDC9"
],
[
"TXNDC9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Iobenguane",
"{u} (Compound) downregulates {v} (Gene)",
"BPHL"
],
[
"BPHL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Iobenguane",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] | Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Iobenguane (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Iobenguane (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Iobenguane (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Iobenguane (Compound) downregulates BPHL (Gene) and BPHL (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Iobenguane (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00279 | DB09481 | 1,152 | 460 | [
"DDInter1074",
"DDInter1113"
] | Liothyronine | Magnesium carbonate | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
1152,
24,
460
]
],
[
[
1152,
24,
1252
],
[
1252,
23,
460
]
],
[
[
1152,
23,
461
],
[
461,
23,
460
]
],
[
[
1152,
62,
88
],
[
88,
23,
460
]
],
[
[
1152,
1,
1191
],
[
1191,
23,
460
]
],
[
[
1152,
24,
260
],
[
260,
63,
460
]
],
[
[
1152,
63,
245
],
[
245,
24,
460
]
],
[
[
1152,
1,
624
],
[
624,
24,
460
]
],
[
[
1152,
24,
959
],
[
959,
24,
460
]
],
[
[
1152,
24,
1231
],
[
1231,
25,
460
]
]
] | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Levodopa"
],
[
"Levodopa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
],
[
"Ferrous sulfate anhydrous",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Liotrix"
],
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium carbonate"
]
]
] | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Liothyronine may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Liothyronine may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Liothyronine (Compound) resembles Levodopa (Compound) and Levodopa may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous and Ferrous sulfate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Liothyronine (Compound) resembles Liotrix (Compound) and Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may lead to a major life threatening interaction when taken with Magnesium carbonate |
DB00530 | DB08827 | 1,195 | 990 | [
"DDInter667",
"DDInter1085"
] | Erlotinib | Lomitapide | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1195,
25,
990
]
],
[
[
1195,
24,
1080
],
[
1080,
1,
990
]
],
[
[
1195,
6,
8374
],
[
8374,
45,
990
]
],
[
[
1195,
21,
28903
],
[
28903,
60,
990
]
],
[
[
1195,
24,
1476
],
[
1476,
63,
990
]
],
[
[
1195,
63,
322
],
[
322,
24,
990
]
],
[
[
1195,
24,
1491
],
[
1491,
24,
990
]
],
[
[
1195,
63,
79
],
[
79,
25,
990
]
],
[
[
1195,
24,
1320
],
[
1320,
64,
990
]
],
[
[
1195,
25,
1510
],
[
1510,
64,
990
]
]
] | [
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} (Compound) resembles {v} (Compound)",
"Lomitapide"
]
],
[
[
"Erlotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lomitapide"
]
],
[
[
"Erlotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Dry skin"
],
[
"Dry skin",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lomitapide"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
]
] | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Erlotinib (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Lomitapide (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Lomitapide
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may lead to a major life threatening interaction when taken with Lomitapide
Erlotinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Lomitapide |
DB00377 | DB09082 | 1,494 | 659 | [
"DDInter1382",
"DDInter1934"
] | Palonosetron | Vilanterol | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
1494,
24,
659
]
],
[
[
1494,
63,
1570
],
[
1570,
24,
659
]
],
[
[
1494,
24,
927
],
[
927,
63,
659
]
],
[
[
1494,
25,
1069
],
[
1069,
24,
659
]
],
[
[
1494,
24,
485
],
[
485,
24,
659
]
],
[
[
1494,
25,
1375
],
[
1375,
63,
659
]
],
[
[
1494,
64,
21
],
[
21,
24,
659
]
],
[
[
1494,
25,
877
],
[
877,
64,
659
]
],
[
[
1494,
25,
17
],
[
17,
25,
659
]
],
[
[
1494,
63,
1570
],
[
1570,
24,
927
],
[
927,
63,
659
]
]
] | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
]
] | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Palonosetron may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Palonosetron may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Palonosetron may lead to a major life threatening interaction when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Palonosetron may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Vilanterol
Palonosetron may lead to a major life threatening interaction when taken with Sotalol and Sotalol may lead to a major life threatening interaction when taken with Vilanterol
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol |
DB00783 | DB01190 | 1,438 | 568 | [
"DDInter679",
"DDInter398"
] | Estradiol | Clindamycin | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays, gels, and creams.[L11485,L11488,L11491, L11494,L11497,L11500,L11503] When used for oral or IM administration, estradiol is commonly synthesized as a pro-drug ester (such as,,,, and ). Because it has a low oral bioavailability on its own, estradiol is commonly formulated with an ester side-chain. (EE) is a synthetic form of estradiol commonly used as the estrogenic component of most combination oral contraceptive pills (OCPs). Ethinyl estradiol is different from estradiol due to its higher | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis. Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample. | Moderate | 1 | [
[
[
1438,
24,
568
]
],
[
[
1438,
6,
8374
],
[
8374,
45,
568
]
],
[
[
1438,
21,
29278
],
[
29278,
60,
568
]
],
[
[
1438,
24,
1132
],
[
1132,
24,
568
]
],
[
[
1438,
24,
609
],
[
609,
63,
568
]
],
[
[
1438,
1,
890
],
[
890,
63,
568
]
],
[
[
1438,
6,
8374
],
[
8374,
45,
609
],
[
609,
63,
568
]
],
[
[
1438,
21,
29278
],
[
29278,
60,
859
],
[
859,
63,
568
]
],
[
[
1438,
21,
28680
],
[
28680,
60,
1208
],
[
1208,
1,
568
]
],
[
[
1438,
21,
28828
],
[
28828,
60,
1236
],
[
1236,
24,
568
]
]
] | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Estradiol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clindamycin"
]
],
[
[
"Estradiol",
"{u} (Compound) causes {v} (Side Effect)",
"Inflammation"
],
[
"Inflammation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clindamycin"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Estradiol",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Estradiol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Estradiol",
"{u} (Compound) causes {v} (Side Effect)",
"Inflammation"
],
[
"Inflammation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Posaconazole"
],
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Estradiol",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lincomycin"
],
[
"Lincomycin",
"{u} (Compound) resembles {v} (Compound)",
"Clindamycin"
]
],
[
[
"Estradiol",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity reaction"
],
[
"Photosensitivity reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
]
] | Estradiol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Estradiol (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Clindamycin (Compound)
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Estradiol (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Estradiol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Estradiol (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Estradiol (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Lincomycin (Compound) and Lincomycin (Compound) resembles Clindamycin (Compound)
Estradiol (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin |
DB06589 | DB08870 | 1,250 | 850 | [
"DDInter1400",
"DDInter228"
] | Pazopanib | Brentuximab vedotin | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease. | Moderate | 1 | [
[
[
1250,
24,
850
]
],
[
[
1250,
24,
788
],
[
788,
24,
850
]
],
[
[
1250,
63,
671
],
[
671,
24,
850
]
],
[
[
1250,
24,
496
],
[
496,
63,
850
]
],
[
[
1250,
64,
1570
],
[
1570,
24,
850
]
],
[
[
1250,
25,
1155
],
[
1155,
63,
850
]
],
[
[
1250,
62,
1247
],
[
1247,
24,
850
]
],
[
[
1250,
25,
1593
],
[
1593,
24,
850
]
],
[
[
1250,
35,
786
],
[
786,
24,
850
]
],
[
[
1250,
25,
1510
],
[
1510,
64,
850
]
]
] | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pazopanib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
]
] | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pazopanib may lead to a major life threatening interaction when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pazopanib may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pazopanib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pazopanib (Compound) resembles Rilpivirine (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pazopanib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin |
DB00393 | DB01082 | 854 | 1,448 | [
"DDInter1295",
"DDInter1713"
] | Nimodipine | Streptomycin | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm. | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis. | Moderate | 1 | [
[
[
854,
24,
1448
]
],
[
[
854,
21,
28680
],
[
28680,
60,
1448
]
],
[
[
854,
24,
361
],
[
361,
24,
1448
]
],
[
[
854,
24,
1532
],
[
1532,
63,
1448
]
],
[
[
854,
24,
1527
],
[
1527,
64,
1448
]
],
[
[
854,
24,
544
],
[
544,
25,
1448
]
],
[
[
854,
24,
416
],
[
416,
74,
1448
]
],
[
[
854,
21,
28680
],
[
28680,
60,
437
],
[
437,
40,
1448
]
],
[
[
854,
21,
28784
],
[
28784,
60,
1682
],
[
1682,
63,
1448
]
],
[
[
854,
24,
361
],
[
361,
1,
437
],
[
437,
40,
1448
]
]
] | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Nimodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Streptomycin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Nimodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amikacin"
],
[
"Amikacin",
"{u} (Compound) resembles {v} (Compound)",
"Streptomycin"
]
],
[
[
"Nimodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ceftaroline fosamil"
],
[
"Ceftaroline fosamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} (Compound) resembles {v} (Compound)",
"Amikacin"
],
[
"Amikacin",
"{u} (Compound) resembles {v} (Compound)",
"Streptomycin"
]
]
] | Nimodipine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Streptomycin (Compound)
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Streptomycin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may lead to a major life threatening interaction when taken with Streptomycin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Streptomycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Nimodipine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Amikacin (Compound) and Amikacin (Compound) resembles Streptomycin (Compound)
Nimodipine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Ceftaroline fosamil (Compound) and Ceftaroline fosamil may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin (Compound) resembles Amikacin (Compound) and Amikacin (Compound) resembles Streptomycin (Compound) |
DB00563 | DB00607 | 663 | 1,249 | [
"DDInter1174",
"DDInter1256"
] | Methotrexate | Nafcillin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections . | Major | 2 | [
[
[
663,
25,
1249
]
],
[
[
663,
25,
319
],
[
319,
1,
1249
]
],
[
[
663,
64,
1667
],
[
1667,
1,
1249
]
],
[
[
663,
25,
1681
],
[
1681,
40,
1249
]
],
[
[
663,
6,
10612
],
[
10612,
45,
1249
]
],
[
[
663,
21,
28792
],
[
28792,
60,
1249
]
],
[
[
663,
63,
168
],
[
168,
23,
1249
]
],
[
[
663,
24,
609
],
[
609,
62,
1249
]
],
[
[
663,
24,
1669
],
[
1669,
63,
1249
]
],
[
[
663,
25,
676
],
[
676,
63,
1249
]
]
] | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nafcillin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amoxicillin"
],
[
"Amoxicillin",
"{u} (Compound) resembles {v} (Compound)",
"Nafcillin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenoxymethylpenicillin"
],
[
"Phenoxymethylpenicillin",
"{u} (Compound) resembles {v} (Compound)",
"Nafcillin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mezlocillin"
],
[
"Mezlocillin",
"{u} (Compound) resembles {v} (Compound)",
"Nafcillin"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Nafcillin"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nafcillin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nafcillin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nafcillin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
]
]
] | Methotrexate may lead to a major life threatening interaction when taken with Amoxicillin and Amoxicillin (Compound) resembles Nafcillin (Compound)
Methotrexate may lead to a major life threatening interaction when taken with Phenoxymethylpenicillin and Phenoxymethylpenicillin (Compound) resembles Nafcillin (Compound)
Methotrexate may lead to a major life threatening interaction when taken with Mezlocillin and Mezlocillin (Compound) resembles Nafcillin (Compound)
Methotrexate (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Nafcillin (Compound)
Methotrexate (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Nafcillin (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Nafcillin
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Nafcillin
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin
Methotrexate may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin |
DB00312 | DB06228 | 1,023 | 792 | [
"DDInter1423",
"DDInter1609"
] | Pentobarbital | Rivaroxaban | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236) | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Moderate | 1 | [
[
[
1023,
24,
792
]
],
[
[
1023,
6,
8374
],
[
8374,
45,
792
]
],
[
[
1023,
21,
28769
],
[
28769,
60,
792
]
],
[
[
1023,
23,
752
],
[
752,
24,
792
]
],
[
[
1023,
24,
79
],
[
79,
24,
792
]
],
[
[
1023,
24,
466
],
[
466,
63,
792
]
],
[
[
1023,
62,
1101
],
[
1101,
24,
792
]
],
[
[
1023,
1,
536
],
[
536,
24,
792
]
],
[
[
1023,
25,
765
],
[
765,
24,
792
]
],
[
[
1023,
24,
129
],
[
129,
64,
792
]
]
] | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rivaroxaban"
]
],
[
[
"Pentobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rivaroxaban"
]
],
[
[
"Pentobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Pentobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Pentobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
]
] | Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rivaroxaban (Compound)
Pentobarbital (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Rivaroxaban (Compound)
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Pentobarbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Pentobarbital may lead to a major life threatening interaction when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Rivaroxaban |
DB00004 | DB08904 | 669 | 375 | [
"DDInter499",
"DDInter342"
] | Denileukin diftitox | Certolizumab pegol | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Major | 2 | [
[
[
669,
25,
375
]
],
[
[
669,
24,
200
],
[
200,
63,
375
]
],
[
[
669,
24,
66
],
[
66,
24,
375
]
],
[
[
669,
25,
1066
],
[
1066,
25,
375
]
],
[
[
669,
24,
563
],
[
563,
25,
375
]
],
[
[
669,
25,
1624
],
[
1624,
64,
375
]
],
[
[
669,
24,
384
],
[
384,
64,
375
]
],
[
[
669,
24,
200
],
[
200,
63,
58
],
[
58,
24,
375
]
],
[
[
669,
24,
66
],
[
66,
23,
1461
],
[
1461,
23,
375
]
],
[
[
669,
24,
599
],
[
599,
24,
200
],
[
200,
63,
375
]
]
] | [
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
],
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
]
] | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Denileukin diftitox may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may lead to a major life threatening interaction when taken with Certolizumab pegol
Denileukin diftitox may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Certolizumab pegol
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Certolizumab pegol
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol |
DB00245 | DB06691 | 357 | 849 | [
"DDInter181",
"DDInter1155"
] | Benzatropine | Mepyramine | Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in one of the phenyl rings produces an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine. Benztropine was developed by USL Pharma and officially approved by the FDA on 1996. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
357,
24,
849
]
],
[
[
357,
24,
1594
],
[
1594,
24,
849
]
],
[
[
357,
1,
358
],
[
358,
24,
849
]
],
[
[
357,
6,
12523
],
[
12523,
45,
849
]
],
[
[
357,
24,
1116
],
[
1116,
63,
849
]
],
[
[
357,
35,
262
],
[
262,
24,
849
]
],
[
[
357,
40,
704
],
[
704,
24,
849
]
],
[
[
357,
74,
352
],
[
352,
24,
849
]
],
[
[
357,
25,
1621
],
[
1621,
25,
849
]
],
[
[
357,
24,
662
],
[
662,
35,
849
]
]
] | [
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Benzatropine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Benzatropine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepyramine"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
]
] | Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Benzatropine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Benzatropine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Benzatropine (Compound) resembles Clidinium (Compound) and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Benzatropine (Compound) resembles Fentanyl (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Benzatropine (Compound) resembles Trospium (Compound) and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Benzatropine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Mepyramine
Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine |
DB00867 | DB14568 | 1,052 | 982 | [
"DDInter1606",
"DDInter1000"
] | Ritodrine | Ivosidenib | Adrenergic beta-agonist used to control premature labor. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Major | 2 | [
[
[
1052,
25,
982
]
],
[
[
1052,
24,
1559
],
[
1559,
24,
982
]
],
[
[
1052,
35,
480
],
[
480,
24,
982
]
],
[
[
1052,
64,
11
],
[
11,
25,
982
]
],
[
[
1052,
24,
124
],
[
124,
25,
982
]
],
[
[
1052,
63,
600
],
[
600,
25,
982
]
],
[
[
1052,
25,
351
],
[
351,
25,
982
]
],
[
[
1052,
24,
1559
],
[
1559,
62,
112
],
[
112,
23,
982
]
],
[
[
1052,
35,
480
],
[
480,
24,
1032
],
[
1032,
24,
982
]
],
[
[
1052,
24,
659
],
[
659,
24,
1032
],
[
1032,
24,
982
]
]
] | [
[
[
"Ritodrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ritodrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ritodrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ritodrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ritodrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
]
] | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Ritodrine (Compound) resembles Formoterol (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Ritodrine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Ivosidenib
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib
Ritodrine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Ivosidenib
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Ritodrine (Compound) resembles Formoterol (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib |
DB01041 | DB08901 | 770 | 1,468 | [
"DDInter1789",
"DDInter1492"
] | Thalidomide | Ponatinib | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
770,
25,
1468
]
],
[
[
770,
24,
478
],
[
478,
24,
1468
]
],
[
[
770,
6,
7524
],
[
7524,
45,
1468
]
],
[
[
770,
7,
7669
],
[
7669,
46,
1468
]
],
[
[
770,
7,
4111
],
[
4111,
57,
1468
]
],
[
[
770,
18,
20113
],
[
20113,
57,
1468
]
],
[
[
770,
21,
29271
],
[
29271,
60,
1468
]
],
[
[
770,
63,
1194
],
[
1194,
23,
1468
]
],
[
[
770,
64,
589
],
[
589,
24,
1468
]
],
[
[
770,
24,
987
],
[
987,
63,
1468
]
]
] | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Thalidomide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Thalidomide",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Thalidomide",
"{u} (Compound) upregulates {v} (Gene)",
"CCND3"
],
[
"CCND3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Thalidomide",
"{u} (Compound) downregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Migraine"
],
[
"Migraine",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
],
[
"Vibrio cholerae CVD 103-HgR strain live antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
]
] | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Thalidomide (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ponatinib (Compound)
Thalidomide (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Ponatinib (Compound)
Thalidomide (Compound) upregulates CCND3 (Gene) and CCND3 (Gene) is downregulated by Ponatinib (Compound)
Thalidomide (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Ponatinib (Compound)
Thalidomide (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Ponatinib (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Thalidomide may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib |
DB00585 | DB00705 | 1,127 | 441 | [
"DDInter1309",
"DDInter496"
] | Nizatidine | Delavirdine | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Moderate | 1 | [
[
[
1127,
24,
441
]
],
[
[
1127,
21,
28709
],
[
28709,
60,
441
]
],
[
[
1127,
23,
1283
],
[
1283,
63,
441
]
],
[
[
1127,
1,
1194
],
[
1194,
63,
441
]
],
[
[
1127,
24,
1040
],
[
1040,
63,
441
]
],
[
[
1127,
63,
1195
],
[
1195,
24,
441
]
],
[
[
1127,
23,
1512
],
[
1512,
24,
441
]
],
[
[
1127,
23,
1468
],
[
1468,
64,
441
]
],
[
[
1127,
24,
478
],
[
478,
64,
441
]
],
[
[
1127,
25,
1250
],
[
1250,
64,
441
]
]
] | [
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Nizatidine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Nizatidine",
"{u} (Compound) resembles {v} (Compound)",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
]
],
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
]
],
[
[
"Nizatidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
]
]
] | Nizatidine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound)
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Nizatidine (Compound) resembles Ranitidine (Compound) and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Delavirdine
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Delavirdine
Nizatidine may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Delavirdine |
DB00519 | DB00741 | 1,638 | 167 | [
"DDInter1843",
"DDInter885"
] | Trandolapril | Hydrocortisone | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Moderate | 1 | [
[
[
1638,
24,
167
]
],
[
[
1638,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1638,
24,
870
],
[
870,
1,
167
]
],
[
[
1638,
63,
251
],
[
251,
40,
167
]
],
[
[
1638,
21,
28642
],
[
28642,
60,
167
]
],
[
[
1638,
23,
1384
],
[
1384,
62,
167
]
],
[
[
1638,
24,
1254
],
[
1254,
63,
167
]
],
[
[
1638,
1,
743
],
[
743,
24,
167
]
],
[
[
1638,
63,
1179
],
[
1179,
24,
167
]
],
[
[
1638,
1,
954
],
[
954,
63,
167
]
]
] | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Trandolapril",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Trandolapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
]
] | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydrocortisone (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Hydrocortisone (Compound)
Trandolapril (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Hydrocortisone (Compound)
Trandolapril may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Trandolapril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Trandolapril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone |
DB01115 | DB06292 | 336 | 549 | [
"DDInter1291",
"DDInter474"
] | Nifedipine | Dapagliflozin | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021. | Moderate | 1 | [
[
[
336,
24,
549
]
],
[
[
336,
24,
1344
],
[
1344,
40,
549
]
],
[
[
336,
6,
9842
],
[
9842,
45,
549
]
],
[
[
336,
21,
28882
],
[
28882,
60,
549
]
],
[
[
336,
63,
467
],
[
467,
23,
549
]
],
[
[
336,
40,
1428
],
[
1428,
24,
549
]
],
[
[
336,
24,
1017
],
[
1017,
63,
549
]
],
[
[
336,
63,
629
],
[
629,
24,
549
]
],
[
[
336,
24,
885
],
[
885,
24,
549
]
],
[
[
336,
25,
913
],
[
913,
63,
549
]
]
] | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Dapagliflozin"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A1"
],
[
"CYP1A1",
"{u} (Gene) is bound by {v} (Compound)",
"Dapagliflozin"
]
],
[
[
"Nifedipine",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dapagliflozin"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
]
] | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Nifedipine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dapagliflozin (Compound)
Nifedipine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dapagliflozin (Compound)
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Nifedipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Nifedipine may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin |
DB00285 | DB08820 | 1,100 | 1,478 | [
"DDInter1927",
"DDInter997"
] | Venlafaxine | Ivacaftor | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venl | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms. | Moderate | 1 | [
[
[
1100,
24,
1478
]
],
[
[
1100,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1100,
21,
29998
],
[
29998,
60,
1478
]
],
[
[
1100,
24,
543
],
[
543,
24,
1478
]
],
[
[
1100,
25,
985
],
[
985,
63,
1478
]
],
[
[
1100,
24,
484
],
[
484,
63,
1478
]
],
[
[
1100,
23,
752
],
[
752,
24,
1478
]
],
[
[
1100,
25,
39
],
[
39,
24,
1478
]
],
[
[
1100,
63,
1324
],
[
1324,
24,
1478
]
],
[
[
1100,
63,
600
],
[
600,
25,
1478
]
]
] | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ivacaftor"
]
],
[
[
"Venlafaxine",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperaesthesia"
],
[
"Hyperaesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ivacaftor"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Venlafaxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
]
] | Venlafaxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Venlafaxine (Compound) causes Hyperaesthesia (Side Effect) and Hyperaesthesia (Side Effect) is caused by Ivacaftor (Compound)
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Venlafaxine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Venlafaxine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor |
DB00289 | DB05294 | 847 | 1,069 | [
"DDInter132",
"DDInter1917"
] | Atomoxetine | Vandetanib | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
847,
25,
1069
]
],
[
[
847,
24,
883
],
[
883,
40,
1069
]
],
[
[
847,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
847,
21,
28719
],
[
28719,
60,
1069
]
],
[
[
847,
23,
112
],
[
112,
23,
1069
]
],
[
[
847,
24,
659
],
[
659,
63,
1069
]
],
[
[
847,
24,
688
],
[
688,
24,
1069
]
],
[
[
847,
40,
126
],
[
126,
24,
1069
]
],
[
[
847,
24,
401
],
[
401,
25,
1069
]
],
[
[
847,
25,
985
],
[
985,
64,
1069
]
]
] | [
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Vandetanib"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vandetanib"
]
],
[
[
"Atomoxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vandetanib"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vandetanib"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
]
] | Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Vandetanib (Compound)
Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Atomoxetine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Vandetanib (Compound)
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vandetanib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Atomoxetine (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Vandetanib
Atomoxetine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Vandetanib |
DB00704 | DB00754 | 267 | 157 | [
"DDInter1263",
"DDInter696"
] | Naltrexone | Ethotoin | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used. | Moderate | 1 | [
[
[
267,
24,
157
]
],
[
[
267,
18,
15501
],
[
15501,
57,
157
]
],
[
[
267,
21,
28763
],
[
28763,
60,
157
]
],
[
[
267,
63,
663
],
[
663,
24,
157
]
],
[
[
267,
24,
384
],
[
384,
63,
157
]
],
[
[
267,
25,
407
],
[
407,
63,
157
]
],
[
[
267,
64,
475
],
[
475,
24,
157
]
],
[
[
267,
25,
1510
],
[
1510,
64,
157
]
],
[
[
267,
63,
600
],
[
600,
25,
157
]
],
[
[
267,
18,
15501
],
[
15501,
17,
10375
],
[
10375,
57,
157
]
]
] | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Naltrexone",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ethotoin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ethotoin"
]
],
[
[
"Naltrexone",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) regulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ethotoin"
]
]
] | Naltrexone (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Ethotoin (Compound)
Naltrexone (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Ethotoin (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Naltrexone may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Naltrexone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Naltrexone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ethotoin
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ethotoin
Naltrexone (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) regulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Ethotoin (Compound) |
DB01069 | DB04855 | 401 | 540 | [
"DDInter1533",
"DDInter602"
] | Promethazine | Dronedarone | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone. | Major | 2 | [
[
[
401,
25,
540
]
],
[
[
401,
64,
347
],
[
347,
40,
540
]
],
[
[
401,
25,
33
],
[
33,
40,
540
]
],
[
[
401,
6,
12523
],
[
12523,
45,
540
]
],
[
[
401,
21,
28828
],
[
28828,
60,
540
]
],
[
[
401,
62,
112
],
[
112,
23,
540
]
],
[
[
401,
63,
473
],
[
473,
24,
540
]
],
[
[
401,
24,
144
],
[
144,
63,
540
]
],
[
[
401,
24,
272
],
[
272,
24,
540
]
],
[
[
401,
23,
286
],
[
286,
63,
540
]
]
] | [
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
]
],
[
[
"Promethazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity reaction"
],
[
"Photosensitivity reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dronedarone"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
]
] | Promethazine may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Promethazine may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Promethazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dronedarone (Compound)
Promethazine (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Dronedarone (Compound)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dronedarone
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone |
DB00514 | DB06700 | 506 | 643 | [
"DDInter527",
"DDInter511"
] | Dextromethorphan | Desvenlafaxine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [venlafaxine]. The major difference is the potential for drug interaction since venlafaxine is mainly metabolized by CYP2D6 while desvenlafaxine is conjugated by UGT; therefore, desvenlafaxine is less likely to cause drug-drug interaction when taken with medications affecting the CYP2D6 pathway. | Major | 2 | [
[
[
506,
25,
643
]
],
[
[
506,
64,
1100
],
[
1100,
1,
643
]
],
[
[
506,
6,
7390
],
[
7390,
45,
643
]
],
[
[
506,
21,
28975
],
[
28975,
60,
643
]
],
[
[
506,
63,
752
],
[
752,
23,
643
]
],
[
[
506,
24,
1311
],
[
1311,
24,
643
]
],
[
[
506,
63,
1018
],
[
1018,
24,
643
]
],
[
[
506,
24,
283
],
[
283,
63,
643
]
],
[
[
506,
63,
73
],
[
73,
25,
643
]
],
[
[
506,
25,
1133
],
[
1133,
25,
643
]
]
] | [
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
]
]
] | Dextromethorphan may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Dextromethorphan (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Desvenlafaxine (Compound)
Dextromethorphan (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Desvenlafaxine (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Desvenlafaxine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Desvenlafaxine
Dextromethorphan may lead to a major life threatening interaction when taken with Granisetron and Granisetron may lead to a major life threatening interaction when taken with Desvenlafaxine |
DB00377 | DB00998 | 1,494 | 404 | [
"DDInter1382",
"DDInter788"
] | Palonosetron | Frovatriptan | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. | Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. | Major | 2 | [
[
[
1494,
25,
404
]
],
[
[
1494,
6,
7950
],
[
7950,
45,
404
]
],
[
[
1494,
21,
28921
],
[
28921,
60,
404
]
],
[
[
1494,
25,
868
],
[
868,
63,
404
]
],
[
[
1494,
24,
1619
],
[
1619,
63,
404
]
],
[
[
1494,
63,
475
],
[
475,
24,
404
]
],
[
[
1494,
25,
1053
],
[
1053,
64,
404
]
],
[
[
1494,
25,
1166
],
[
1166,
25,
404
]
],
[
[
1494,
6,
7950
],
[
7950,
45,
868
],
[
868,
63,
404
]
],
[
[
1494,
21,
28921
],
[
28921,
60,
868
],
[
868,
63,
404
]
]
] | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Frovatriptan"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Frovatriptan"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Frovatriptan"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Frovatriptan"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Frovatriptan"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Frovatriptan"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Frovatriptan"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Frovatriptan"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Frovatriptan"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Frovatriptan"
]
]
] | Palonosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Frovatriptan (Compound)
Palonosetron (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Frovatriptan (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Frovatriptan
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Frovatriptan
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Frovatriptan
Palonosetron may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Frovatriptan
Palonosetron may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Frovatriptan
Palonosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Frovatriptan
Palonosetron (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Frovatriptan |
DB00332 | DB00777 | 1,089 | 146 | [
"DDInter970",
"DDInter1537"
] | Ipratropium | Propiomazine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891] | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. | Moderate | 1 | [
[
[
1089,
24,
146
]
],
[
[
1089,
24,
508
],
[
508,
1,
146
]
],
[
[
1089,
24,
401
],
[
401,
63,
146
]
],
[
[
1089,
24,
104
],
[
104,
40,
146
]
],
[
[
1089,
6,
7992
],
[
7992,
45,
146
]
],
[
[
1089,
24,
1442
],
[
1442,
24,
146
]
],
[
[
1089,
63,
352
],
[
352,
24,
146
]
],
[
[
1089,
35,
19
],
[
19,
24,
146
]
],
[
[
1089,
24,
508
],
[
508,
35,
401
],
[
401,
63,
146
]
],
[
[
1089,
24,
401
],
[
401,
74,
508
],
[
508,
1,
146
]
]
] | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Ipratropium",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
"Propiomazine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Ipratropium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
]
] | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Propiomazine (Compound)
Ipratropium (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Propiomazine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Ipratropium (Compound) resembles Hyoscyamine (Compound) and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Promethazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) resembles Promazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound) |
DB11793 | DB12364 | 738 | 1,421 | [
"DDInter1297",
"DDInter200"
] | Niraparib | Betrixaban | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Moderate | 1 | [
[
[
738,
24,
1421
]
],
[
[
738,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
738,
63,
759
],
[
759,
24,
1421
]
],
[
[
738,
63,
714
],
[
714,
25,
1421
]
],
[
[
738,
24,
1650
],
[
1650,
64,
1421
]
],
[
[
738,
24,
1017
],
[
1017,
63,
1091
],
[
1091,
24,
1421
]
],
[
[
738,
63,
759
],
[
759,
25,
1513
],
[
1513,
24,
1421
]
],
[
[
738,
63,
1097
],
[
1097,
63,
1513
],
[
1513,
24,
1421
]
],
[
[
738,
24,
1406
],
[
1406,
64,
1091
],
[
1091,
24,
1421
]
],
[
[
738,
24,
1033
],
[
1033,
24,
1017
],
[
1017,
24,
1421
]
]
] | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
],
[
"Avapritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apremilast"
],
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
],
[
"Lasmiditan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
],
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
]
] | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Betrixaban
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone may lead to a major life threatening interaction when taken with Apremilast and Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Apremilast and Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib and Neratinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban |
DB09036 | DB10429 | 812 | 200 | [
"DDInter1668",
"DDInter282"
] | Siltuximab | Candida albicans | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks. | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
812,
24,
200
]
],
[
[
812,
63,
1683
],
[
1683,
24,
200
]
],
[
[
812,
64,
976
],
[
976,
24,
200
]
],
[
[
812,
24,
270
],
[
270,
63,
200
]
],
[
[
812,
25,
676
],
[
676,
63,
200
]
],
[
[
812,
63,
1683
],
[
1683,
63,
1096
],
[
1096,
24,
200
]
],
[
[
812,
64,
976
],
[
976,
64,
1096
],
[
1096,
24,
200
]
],
[
[
812,
63,
147
],
[
147,
24,
1683
],
[
1683,
24,
200
]
],
[
[
812,
64,
1064
],
[
1064,
25,
1096
],
[
1096,
24,
200
]
],
[
[
812,
24,
270
],
[
270,
63,
1096
],
[
1096,
24,
200
]
]
] | [
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
]
] | Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Siltuximab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Siltuximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Siltuximab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Siltuximab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans |
DB00448 | DB00582 | 1,215 | 1,622 | [
"DDInter1022",
"DDInter1946"
] | Lansoprazole | Voriconazole | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion. | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002. | Moderate | 1 | [
[
[
1215,
24,
1622
]
],
[
[
1215,
6,
8374
],
[
8374,
45,
1622
]
],
[
[
1215,
21,
28957
],
[
28957,
60,
1622
]
],
[
[
1215,
24,
1287
],
[
1287,
62,
1622
]
],
[
[
1215,
25,
663
],
[
663,
24,
1622
]
],
[
[
1215,
24,
1419
],
[
1419,
63,
1622
]
],
[
[
1215,
62,
1031
],
[
1031,
24,
1622
]
],
[
[
1215,
63,
883
],
[
883,
24,
1622
]
],
[
[
1215,
40,
660
],
[
660,
63,
1622
]
],
[
[
1215,
40,
837
],
[
837,
24,
1622
]
]
] | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Lansoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Voriconazole"
]
],
[
[
"Lansoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Arthralgia"
],
[
"Arthralgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Voriconazole"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Voriconazole"
]
],
[
[
"Lansoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
]
] | Lansoprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Voriconazole (Compound)
Lansoprazole (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Voriconazole (Compound)
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Lansoprazole may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Lansoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Lansoprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole |
DB00307 | DB00490 | 1,101 | 946 | [
"DDInter202",
"DDInter254"
] | Bexarotene | Buspirone | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'. First synthesized in 1968 then patented in 1975, it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety. It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate. The potential use of buspirone in combination with [melatonin] in depression and cognitive impairment via promoting neurogenesis has also been investigated. | Moderate | 1 | [
[
[
1101,
24,
946
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
946
]
],
[
[
1101,
21,
29209
],
[
29209,
60,
946
]
],
[
[
1101,
23,
609
],
[
609,
63,
946
]
],
[
[
1101,
24,
927
],
[
927,
63,
946
]
],
[
[
1101,
62,
600
],
[
600,
24,
946
]
],
[
[
1101,
25,
1476
],
[
1476,
63,
946
]
],
[
[
1101,
23,
1051
],
[
1051,
24,
946
]
],
[
[
1101,
24,
1133
],
[
1133,
64,
946
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
820
],
[
820,
63,
946
]
]
] | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Buspirone"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Buspirone"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Buspirone"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
]
] | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Buspirone (Compound)
Bexarotene (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Buspirone (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Bexarotene may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may lead to a major life threatening interaction when taken with Buspirone
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone |
DB00015 | DB00054 | 582 | 1,432 | [
"DDInter1585",
"DDInter6"
] | Reteplase | Abciximab | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. | Major | 2 | [
[
[
582,
25,
1432
]
],
[
[
582,
23,
539
],
[
539,
62,
1432
]
],
[
[
582,
24,
714
],
[
714,
63,
1432
]
],
[
[
582,
24,
1595
],
[
1595,
24,
1432
]
],
[
[
582,
64,
942
],
[
942,
24,
1432
]
],
[
[
582,
25,
802
],
[
802,
64,
1432
]
],
[
[
582,
24,
1347
],
[
1347,
64,
1432
]
],
[
[
582,
64,
1578
],
[
1578,
25,
1432
]
],
[
[
582,
23,
539
],
[
539,
62,
714
],
[
714,
63,
1432
]
],
[
[
582,
24,
714
],
[
714,
23,
539
],
[
539,
62,
1432
]
]
] | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abciximab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abciximab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
],
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abciximab"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abciximab"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
],
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abciximab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abciximab"
]
]
] | Reteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Abciximab
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Abciximab
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Abciximab
Reteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Abciximab
Reteplase may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Abciximab
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Abciximab
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Abciximab
Reteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Abciximab
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Abciximab |
DB00561 | DB11640 | 1,048 | 1,267 | [
"DDInter591",
"DDInter64"
] | Doxapram | Amifampridine | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscular disorders, including Lambert–Eaton myasthenic syndrome (LEMS), has been investigated in the 1980s . Amifampridine phosphate is a more stable salt that serves as an active ingredient of EMA-approved Firdapse, which was previously marketed as Zenas. It is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally given as oral tablets in divided doses, three or four times a day. Firdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 . LEMS is a rare auto-immune disorder of the neuromuscular junction that is characterized by proximal muscle weakness, depressed tendon reflexes, and posttetanic potentiation in addition to autonomic dysfunction . About 50-60% of the patients develop more rapidly progressive LEMS and small cell lung cancer, which influences the prognosis . Patients with LEMS develop serum antibodies against presynaptic P/Q-type voltage-gated calcium channels, leading to decreased presynaptic calcium levels and reduced quantal release of acetylcholine, which is mainly responsible for causing symptoms of LEMS . Reduced acetylcholine release at the neuromuscular junction leads to decreased frequency of miniature endplate potentials of normal amplitude, and insufficient acetylcholine levels for the activation of postsynaptic muscle fibers following a single nerve impulse . This leads to the reduction of the compound muscle action potential (CMAP) . Treatment for LEMS include immunotherapy such as conventional immunosuppression or intravenous immunoglobulins, however such treatments are recommended in patients in whom symptomatic treatment would not suffice . Amifampridine is the nonimmune treatment options for LEMS. In phase III clinical trials of adult patients with LEMS, treatment of amifampridine significantly improved symptoms of LEMS compared to placebo with good tolerance . It was demonstrated in clinical studies involving healthy volunteers that the pharmacokinetics and systemic exposure to amifampridine is affected by the genetic differences in N-acetyl-transferase (NAT) enzymes (acetylator phenotype) and NAT2 genotype, which is subject to genetic variation . Slow acetylators were at higher risk for experiencing drug-associated adverse reactions, such as paresthesias, nausea, and headache . | Moderate | 1 | [
[
[
1048,
24,
1267
]
],
[
[
1048,
63,
1466
],
[
1466,
24,
1267
]
],
[
[
1048,
24,
1383
],
[
1383,
24,
1267
]
],
[
[
1048,
25,
497
],
[
497,
25,
1267
]
],
[
[
1048,
63,
1466
],
[
1466,
63,
999
],
[
999,
24,
1267
]
],
[
[
1048,
24,
1383
],
[
1383,
24,
407
],
[
407,
24,
1267
]
],
[
[
1048,
63,
1503
],
[
1503,
24,
407
],
[
407,
24,
1267
]
],
[
[
1048,
24,
1662
],
[
1662,
63,
1220
],
[
1220,
24,
1267
]
],
[
[
1048,
24,
22
],
[
22,
62,
1220
],
[
1220,
24,
1267
]
],
[
[
1048,
25,
497
],
[
497,
64,
1220
],
[
1220,
24,
1267
]
]
] | [
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amifampridine"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
]
] | Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Doxapram may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Amifampridine
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Doxapram may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine |
DB00315 | DB01191 | 767 | 1,039 | [
"DDInter1969",
"DDInter518"
] | Zolmitriptan | Dexfenfluramine | Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan. Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment. Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. | Major | 2 | [
[
[
767,
25,
1039
]
],
[
[
767,
6,
7950
],
[
7950,
45,
1039
]
],
[
[
767,
24,
868
],
[
868,
63,
1039
]
],
[
[
767,
63,
702
],
[
702,
24,
1039
]
],
[
[
767,
25,
222
],
[
222,
25,
1039
]
],
[
[
767,
25,
1629
],
[
1629,
64,
1039
]
],
[
[
767,
1,
742
],
[
742,
25,
1039
]
],
[
[
767,
6,
7950
],
[
7950,
45,
181
],
[
181,
1,
1039
]
],
[
[
767,
24,
868
],
[
868,
63,
1529
],
[
1529,
64,
1039
]
],
[
[
767,
63,
702
],
[
702,
6,
7950
],
[
7950,
45,
1039
]
]
] | [
[
[
"Zolmitriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Dexfenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} (Compound) resembles {v} (Compound)",
"Rizatriptan"
],
[
"Rizatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Cinacalcet"
],
[
"Cinacalcet",
"{u} (Compound) resembles {v} (Compound)",
"Dexfenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Dexfenfluramine"
]
]
] | Zolmitriptan (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dexfenfluramine (Compound)
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Zolmitriptan may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Dexfenfluramine
Zolmitriptan may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Dexfenfluramine
Zolmitriptan (Compound) resembles Rizatriptan (Compound) and Rizatriptan may lead to a major life threatening interaction when taken with Dexfenfluramine
Zolmitriptan (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cinacalcet (Compound) and Cinacalcet (Compound) resembles Dexfenfluramine (Compound)
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dexfenfluramine (Compound) |
DB08901 | DB11627 | 1,468 | 1,367 | [
"DDInter1492",
"DDInter860"
] | Ponatinib | Hepatitis B Vaccine (Recombinant) | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier. Transmission of the virus occurs through percutaneous contact with contaminated blood, serum or plasma. Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen. There is no specific treatment for hepatitis. The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. Viral hepatitis caused by hepatitis B virus is a major worldwide health problem, though the incidence and epidemiology vary widely among geographical areas and population subgroups. In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier state). Certain population subgroups in these areas, however, are at high risk (see Indications and Clinical Use). In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%. It is estimated that the reservoir of persistent hepatitis B surface antigen carriers amounts to 350 million people worldwide. Carriers are at a high risk of developing chronic liver disease which may lead to cirrhosis or primary hepatocellular carcinoma. A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6 to14 years following a nationwide hepatitis B vaccination in Taiwan. This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma. Vaccination against hepatitis B is expected in the long term to reduce the overall incidence of both hepatitis B and the chronic complications such as chronic active hepatitis and cirrhosis. | Moderate | 1 | [
[
[
1468,
24,
1367
]
],
[
[
1468,
63,
1560
],
[
1560,
24,
1367
]
],
[
[
1468,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1468,
24,
1480
],
[
1480,
24,
1367
]
],
[
[
1468,
24,
119
],
[
119,
63,
1367
]
],
[
[
1468,
25,
375
],
[
375,
24,
1367
]
],
[
[
1468,
74,
1419
],
[
1419,
24,
1367
]
],
[
[
1468,
25,
405
],
[
405,
63,
1367
]
],
[
[
1468,
63,
1560
],
[
1560,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
1468,
64,
1064
],
[
1064,
36,
1083
],
[
1083,
24,
1367
]
]
] | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ponatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
]
] | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ponatinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ponatinib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ponatinib (Compound) resembles Imatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ponatinib may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ponatinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) resembles Trifluridine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) |
DB08931 | DB12015 | 947 | 1,033 | [
"DDInter1600",
"DDInter53"
] | Riociguat | Alpelisib | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III. Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy. | Moderate | 1 | [
[
[
947,
24,
1033
]
],
[
[
947,
63,
1344
],
[
1344,
24,
1033
]
],
[
[
947,
25,
760
],
[
760,
24,
1033
]
],
[
[
947,
24,
982
],
[
982,
63,
1033
]
],
[
[
947,
24,
1450
],
[
1450,
24,
1033
]
],
[
[
947,
63,
129
],
[
129,
25,
1033
]
],
[
[
947,
24,
913
],
[
913,
25,
1033
]
],
[
[
947,
63,
1344
],
[
1344,
63,
1254
],
[
1254,
24,
1033
]
],
[
[
947,
63,
837
],
[
837,
24,
1335
],
[
1335,
24,
1033
]
],
[
[
947,
25,
760
],
[
760,
64,
1135
],
[
1135,
23,
1033
]
]
] | [
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Riociguat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Riociguat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alpelisib"
]
]
] | Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Riociguat may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Alpelisib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Alpelisib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Riociguat may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib |
DB00563 | DB00621 | 663 | 1,026 | [
"DDInter1174",
"DDInter1357"
] | Methotrexate | Oxandrolone | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | A synthetic hormone with anabolic and androgenic properties. | Moderate | 1 | [
[
[
663,
24,
1026
]
],
[
[
663,
24,
1546
],
[
1546,
1,
1026
]
],
[
[
663,
21,
29956
],
[
29956,
60,
1026
]
],
[
[
663,
24,
671
],
[
671,
63,
1026
]
],
[
[
663,
63,
482
],
[
482,
24,
1026
]
],
[
[
663,
24,
175
],
[
175,
24,
1026
]
],
[
[
663,
25,
1512
],
[
1512,
24,
1026
]
],
[
[
663,
25,
1510
],
[
1510,
64,
1026
]
],
[
[
663,
24,
350
],
[
350,
64,
1026
]
],
[
[
663,
23,
126
],
[
126,
64,
1026
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Oxandrolone"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Erectile dysfunction"
],
[
"Erectile dysfunction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxandrolone"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxandrolone"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxandrolone"
]
],
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxandrolone"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Oxandrolone (Compound)
Methotrexate (Compound) causes Erectile dysfunction (Side Effect) and Erectile dysfunction (Side Effect) is caused by Oxandrolone (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Methotrexate may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Methotrexate may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Oxandrolone
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Oxandrolone
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Oxandrolone |
DB00497 | DB11186 | 828 | 1,609 | [
"DDInter1366",
"DDInter1427"
] | Oxycodone | Pentoxyverine | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed. | Moderate | 1 | [
[
[
828,
24,
1609
]
],
[
[
828,
40,
314
],
[
314,
24,
1609
]
],
[
[
828,
24,
104
],
[
104,
24,
1609
]
],
[
[
828,
63,
999
],
[
999,
24,
1609
]
],
[
[
828,
1,
560
],
[
560,
24,
1609
]
],
[
[
828,
64,
475
],
[
475,
24,
1609
]
],
[
[
828,
25,
1053
],
[
1053,
25,
1609
]
],
[
[
828,
40,
314
],
[
314,
24,
104
],
[
104,
24,
1609
]
],
[
[
828,
24,
104
],
[
104,
63,
314
],
[
314,
24,
1609
]
],
[
[
828,
63,
999
],
[
999,
24,
314
],
[
314,
24,
1609
]
]
] | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
]
] | Oxycodone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Oxycodone (Compound) resembles Oxymorphone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Oxycodone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Oxycodone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Pentoxyverine
Oxycodone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine |
DB09078 | DB11915 | 1,228 | 1,293 | [
"DDInter1036",
"DDInter1909"
] | Lenvatinib | Valbenazine | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg. | Moderate | 1 | [
[
[
1228,
24,
1293
]
],
[
[
1228,
62,
112
],
[
112,
23,
1293
]
],
[
[
1228,
24,
710
],
[
710,
63,
1293
]
],
[
[
1228,
63,
521
],
[
521,
24,
1293
]
],
[
[
1228,
24,
603
],
[
603,
24,
1293
]
],
[
[
1228,
63,
129
],
[
129,
25,
1293
]
],
[
[
1228,
25,
985
],
[
985,
25,
1293
]
],
[
[
1228,
64,
1487
],
[
1487,
25,
1293
]
],
[
[
1228,
24,
913
],
[
913,
25,
1293
]
],
[
[
1228,
25,
877
],
[
877,
64,
1293
]
]
] | [
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Lenvatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Valbenazine"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
]
] | Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Valbenazine
Lenvatinib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Valbenazine
Lenvatinib may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Valbenazine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Valbenazine
Lenvatinib may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Valbenazine |
DB00372 | DB04948 | 999 | 1,084 | [
"DDInter1793",
"DDInter1083"
] | Thiethylperazine | Lofexidine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018. | Moderate | 1 | [
[
[
999,
24,
1084
]
],
[
[
999,
24,
1617
],
[
1617,
1,
1084
]
],
[
[
999,
25,
1311
],
[
1311,
24,
1084
]
],
[
[
999,
63,
701
],
[
701,
24,
1084
]
],
[
[
999,
24,
530
],
[
530,
24,
1084
]
],
[
[
999,
24,
1450
],
[
1450,
63,
1084
]
],
[
[
999,
23,
286
],
[
286,
63,
1084
]
],
[
[
999,
24,
1617
],
[
1617,
40,
1020
],
[
1020,
1,
1084
]
],
[
[
999,
24,
1020
],
[
1020,
1,
1617
],
[
1617,
1,
1084
]
],
[
[
999,
25,
1311
],
[
1311,
63,
1617
],
[
1617,
1,
1084
]
]
] | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[
"Apraclonidine",
"{u} (Compound) resembles {v} (Compound)",
"Lofexidine"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[
"Apraclonidine",
"{u} (Compound) resembles {v} (Compound)",
"Clonidine"
],
[
"Clonidine",
"{u} (Compound) resembles {v} (Compound)",
"Lofexidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
[
"Clonidine",
"{u} (Compound) resembles {v} (Compound)",
"Apraclonidine"
],
[
"Apraclonidine",
"{u} (Compound) resembles {v} (Compound)",
"Lofexidine"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[
"Apraclonidine",
"{u} (Compound) resembles {v} (Compound)",
"Lofexidine"
]
]
] | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Clonidine (Compound) and Clonidine (Compound) resembles Lofexidine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Apraclonidine (Compound) and Apraclonidine (Compound) resembles Lofexidine (Compound)
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound) |
DB00480 | DB08899 | 1,668 | 129 | [
"DDInter1035",
"DDInter649"
] | Lenalidomide | Enzalutamide | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
1668,
24,
129
]
],
[
[
1668,
6,
4973
],
[
4973,
45,
129
]
],
[
[
1668,
21,
29377
],
[
29377,
60,
129
]
],
[
[
1668,
25,
1510
],
[
1510,
24,
129
]
],
[
[
1668,
64,
1463
],
[
1463,
24,
129
]
],
[
[
1668,
63,
79
],
[
79,
24,
129
]
],
[
[
1668,
24,
242
],
[
242,
63,
129
]
],
[
[
1668,
24,
869
],
[
869,
24,
129
]
],
[
[
1668,
25,
192
],
[
192,
63,
129
]
],
[
[
1668,
23,
126
],
[
126,
24,
129
]
]
] | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Lenalidomide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Lenalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal pain"
],
[
"Musculoskeletal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esterified estrogens"
],
[
"Esterified estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Lenalidomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
]
] | Lenalidomide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Enzalutamide (Compound)
Lenalidomide (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Lenalidomide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Lenalidomide may lead to a major life threatening interaction when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Lenalidomide may lead to a major life threatening interaction when taken with Esterified estrogens and Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB00651 | DB00960 | 746 | 887 | [
"DDInter613",
"DDInter1471"
] | Dyphylline | Pindolol | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s. Pindolol was granted FDA approval on 3 September 1982. | Major | 2 | [
[
[
746,
25,
887
]
],
[
[
746,
64,
726
],
[
726,
1,
887
]
],
[
[
746,
25,
819
],
[
819,
40,
887
]
],
[
[
746,
24,
1148
],
[
1148,
63,
887
]
],
[
[
746,
64,
88
],
[
88,
40,
887
]
],
[
[
746,
21,
28809
],
[
28809,
60,
887
]
],
[
[
746,
23,
22
],
[
22,
63,
887
]
],
[
[
746,
24,
1674
],
[
1674,
25,
887
]
],
[
[
746,
24,
688
],
[
688,
64,
887
]
],
[
[
746,
40,
1031
],
[
1031,
25,
887
]
]
] | [
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
]
],
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
]
],
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
]
],
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
]
],
[
[
"Dyphylline",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pindolol"
]
],
[
[
"Dyphylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
]
],
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
]
],
[
[
"Dyphylline",
"{u} (Compound) resembles {v} (Compound)",
"Theophylline"
],
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
]
]
] | Dyphylline may lead to a major life threatening interaction when taken with Betaxolol and Betaxolol (Compound) resembles Pindolol (Compound)
Dyphylline may lead to a major life threatening interaction when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pindolol
Dyphylline may lead to a major life threatening interaction when taken with Metoprolol and Metoprolol (Compound) resembles Pindolol (Compound)
Dyphylline (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Pindolol (Compound)
Dyphylline may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may lead to a major life threatening interaction when taken with Pindolol
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may lead to a major life threatening interaction when taken with Pindolol
Dyphylline (Compound) resembles Theophylline (Compound) and Theophylline may lead to a major life threatening interaction when taken with Pindolol |
DB01175 | DB12245 | 318 | 823 | [
"DDInter672",
"DDInter1863"
] | Escitalopram | Triclabendazole | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Major | 2 | [
[
[
318,
25,
823
]
],
[
[
318,
62,
112
],
[
112,
23,
823
]
],
[
[
318,
64,
1010
],
[
1010,
24,
823
]
],
[
[
318,
24,
28
],
[
28,
24,
823
]
],
[
[
318,
25,
77
],
[
77,
24,
823
]
],
[
[
318,
63,
543
],
[
543,
24,
823
]
],
[
[
318,
25,
1619
],
[
1619,
63,
823
]
],
[
[
318,
25,
868
],
[
868,
25,
823
]
],
[
[
318,
64,
702
],
[
702,
25,
823
]
],
[
[
318,
25,
982
],
[
982,
64,
823
]
]
] | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
]
] | Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Escitalopram may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Escitalopram may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Escitalopram may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Escitalopram may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole
Escitalopram may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Triclabendazole
Escitalopram may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Triclabendazole |
DB06228 | DB08881 | 792 | 868 | [
"DDInter1609",
"DDInter1925"
] | Rivaroxaban | Vemurafenib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Moderate | 1 | [
[
[
792,
24,
868
]
],
[
[
792,
6,
8374
],
[
8374,
45,
868
]
],
[
[
792,
21,
28847
],
[
28847,
60,
868
]
],
[
[
792,
63,
122
],
[
122,
23,
868
]
],
[
[
792,
25,
578
],
[
578,
24,
868
]
],
[
[
792,
25,
760
],
[
760,
63,
868
]
],
[
[
792,
63,
441
],
[
441,
24,
868
]
],
[
[
792,
24,
1040
],
[
1040,
63,
868
]
],
[
[
792,
24,
655
],
[
655,
24,
868
]
],
[
[
792,
64,
998
],
[
998,
24,
868
]
]
] | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rivaroxaban",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Rivaroxaban",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
]
] | Rivaroxaban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Rivaroxaban (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Rivaroxaban may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Rivaroxaban may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Rivaroxaban may lead to a major life threatening interaction when taken with Phenylbutazone and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib |
DB09048 | DB12015 | 555 | 1,033 | [
"DDInter1284",
"DDInter53"
] | Netupitant | Alpelisib | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy. | Moderate | 1 | [
[
[
555,
24,
1033
]
],
[
[
555,
25,
1135
],
[
1135,
23,
1033
]
],
[
[
555,
24,
951
],
[
951,
24,
1033
]
],
[
[
555,
63,
896
],
[
896,
24,
1033
]
],
[
[
555,
23,
760
],
[
760,
24,
1033
]
],
[
[
555,
64,
594
],
[
594,
24,
1033
]
],
[
[
555,
24,
1017
],
[
1017,
63,
1033
]
],
[
[
555,
62,
1101
],
[
1101,
24,
1033
]
],
[
[
555,
25,
927
],
[
927,
24,
1033
]
],
[
[
555,
23,
466
],
[
466,
63,
1033
]
]
] | [
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alpelisib"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
]
] | Netupitant may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Netupitant may cause a minor interaction that can limit clinical effects when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Netupitant may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Netupitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Netupitant may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Netupitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib |
DB06228 | DB08899 | 792 | 129 | [
"DDInter1609",
"DDInter649"
] | Rivaroxaban | Enzalutamide | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Major | 2 | [
[
[
792,
25,
129
]
],
[
[
792,
6,
8374
],
[
8374,
45,
129
]
],
[
[
792,
21,
28703
],
[
28703,
60,
129
]
],
[
[
792,
63,
851
],
[
851,
24,
129
]
],
[
[
792,
64,
1512
],
[
1512,
24,
129
]
],
[
[
792,
24,
1320
],
[
1320,
63,
129
]
],
[
[
792,
24,
875
],
[
875,
24,
129
]
],
[
[
792,
25,
1468
],
[
1468,
63,
129
]
],
[
[
792,
25,
292
],
[
292,
24,
129
]
],
[
[
792,
62,
307
],
[
307,
24,
129
]
]
] | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rivaroxaban",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Rivaroxaban",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rivaroxaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
]
] | Rivaroxaban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Rivaroxaban (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rivaroxaban may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rivaroxaban may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rivaroxaban may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB00754 | DB06691 | 157 | 849 | [
"DDInter696",
"DDInter1155"
] | Ethotoin | Mepyramine | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
157,
24,
849
]
],
[
[
157,
63,
1594
],
[
1594,
24,
849
]
],
[
[
157,
24,
272
],
[
272,
24,
849
]
],
[
[
157,
40,
499
],
[
499,
24,
849
]
],
[
[
157,
24,
407
],
[
407,
63,
849
]
],
[
[
157,
1,
697
],
[
697,
24,
849
]
],
[
[
157,
63,
662
],
[
662,
35,
849
]
],
[
[
157,
24,
100
],
[
100,
35,
849
]
],
[
[
157,
63,
1594
],
[
1594,
1,
11775
],
[
11775,
40,
849
]
],
[
[
157,
24,
272
],
[
272,
1,
11775
],
[
11775,
40,
849
]
]
] | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethotoin",
"{u} (Compound) resembles {v} (Compound)",
"Phensuximide"
],
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethotoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
]
] | Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ethotoin (Compound) resembles Phensuximide (Compound) and Phensuximide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ethotoin (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound) |
DB08827 | DB11703 | 990 | 405 | [
"DDInter1085",
"DDInter9"
] | Lomitapide | Acalabrutinib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib . | Moderate | 1 | [
[
[
990,
24,
405
]
],
[
[
990,
64,
1324
],
[
1324,
24,
405
]
],
[
[
990,
24,
951
],
[
951,
24,
405
]
],
[
[
990,
24,
1297
],
[
1297,
63,
405
]
],
[
[
990,
25,
484
],
[
484,
63,
405
]
],
[
[
990,
63,
1194
],
[
1194,
24,
405
]
],
[
[
990,
25,
868
],
[
868,
24,
405
]
],
[
[
990,
25,
384
],
[
384,
25,
405
]
],
[
[
990,
63,
126
],
[
126,
25,
405
]
],
[
[
990,
25,
710
],
[
710,
64,
405
]
]
] | [
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
]
] | Lomitapide may lead to a major life threatening interaction when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Lomitapide may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Lomitapide may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Lomitapide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Acalabrutinib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Acalabrutinib
Lomitapide may lead to a major life threatening interaction when taken with Binimetinib and Binimetinib may lead to a major life threatening interaction when taken with Acalabrutinib |
DB00445 | DB00757 | 322 | 1,166 | [
"DDInter655",
"DDInter581"
] | Epirubicin | Dolasetron | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. | Major | 2 | [
[
[
322,
25,
1166
]
],
[
[
322,
7,
6952
],
[
6952,
46,
1166
]
],
[
[
322,
21,
28726
],
[
28726,
60,
1166
]
],
[
[
322,
25,
752
],
[
752,
23,
1166
]
],
[
[
322,
24,
463
],
[
463,
62,
1166
]
],
[
[
322,
23,
1247
],
[
1247,
62,
1166
]
],
[
[
322,
24,
479
],
[
479,
63,
1166
]
],
[
[
322,
63,
867
],
[
867,
24,
1166
]
],
[
[
322,
24,
1516
],
[
1516,
24,
1166
]
],
[
[
322,
25,
770
],
[
770,
63,
1166
]
]
] | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dolasetron"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Oliguria"
],
[
"Oliguria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dolasetron"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolasetron"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolasetron"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolasetron"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Galantamine"
],
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
]
] | Epirubicin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Dolasetron (Compound)
Epirubicin (Compound) causes Oliguria (Side Effect) and Oliguria (Side Effect) is caused by Dolasetron (Compound)
Epirubicin may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Dolasetron
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Dolasetron
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Dolasetron
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Galantamine and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
Epirubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron |
DB00108 | DB15091 | 1,066 | 676 | [
"DDInter1268",
"DDInter1901"
] | Natalizumab | Upadacitinib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
1066,
25,
676
]
],
[
[
1066,
23,
1193
],
[
1193,
23,
676
]
],
[
[
1066,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1066,
64,
1184
],
[
1184,
25,
676
]
],
[
[
1066,
25,
503
],
[
503,
25,
676
]
],
[
[
1066,
25,
899
],
[
899,
64,
676
]
],
[
[
1066,
23,
1193
],
[
1193,
62,
1184
],
[
1184,
25,
676
]
],
[
[
1066,
24,
1430
],
[
1430,
63,
1184
],
[
1184,
25,
676
]
],
[
[
1066,
64,
1184
],
[
1184,
23,
1193
],
[
1193,
23,
676
]
],
[
[
1066,
25,
503
],
[
503,
63,
1430
],
[
1430,
24,
676
]
]
] | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisocabtagene maraleucel"
],
[
"Lisocabtagene maraleucel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
]
] | Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Natalizumab may lead to a major life threatening interaction when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Natalizumab may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Upadacitinib
Natalizumab may lead to a major life threatening interaction when taken with Lisocabtagene maraleucel and Lisocabtagene maraleucel may lead to a major life threatening interaction when taken with Upadacitinib
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Natalizumab may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Natalizumab may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib |
DB00574 | DB06228 | 121 | 792 | [
"DDInter717",
"DDInter1609"
] | Fenfluramine | Rivaroxaban | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Moderate | 1 | [
[
[
121,
24,
792
]
],
[
[
121,
25,
453
],
[
453,
40,
792
]
],
[
[
121,
24,
1670
],
[
1670,
63,
792
]
],
[
[
121,
24,
540
],
[
540,
24,
792
]
],
[
[
121,
25,
901
],
[
901,
24,
792
]
],
[
[
121,
64,
109
],
[
109,
24,
792
]
],
[
[
121,
25,
643
],
[
643,
63,
792
]
],
[
[
121,
63,
1324
],
[
1324,
24,
792
]
],
[
[
121,
24,
292
],
[
292,
64,
792
]
],
[
[
121,
24,
885
],
[
885,
25,
792
]
]
] | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Linezolid"
],
[
"Linezolid",
"{u} (Compound) resembles {v} (Compound)",
"Rivaroxaban"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
]
] | Fenfluramine may lead to a major life threatening interaction when taken with Linezolid and Linezolid (Compound) resembles Rivaroxaban (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Fenfluramine may lead to a major life threatening interaction when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Fenfluramine may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Fenfluramine may lead to a major life threatening interaction when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Rivaroxaban
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Rivaroxaban |
DB00757 | DB09330 | 1,166 | 985 | [
"DDInter581",
"DDInter1352"
] | Dolasetron | Osimertinib | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
1166,
25,
985
]
],
[
[
1166,
23,
1247
],
[
1247,
23,
985
]
],
[
[
1166,
24,
480
],
[
480,
24,
985
]
],
[
[
1166,
24,
657
],
[
657,
63,
985
]
],
[
[
1166,
64,
1181
],
[
1181,
24,
985
]
],
[
[
1166,
63,
62
],
[
62,
24,
985
]
],
[
[
1166,
25,
704
],
[
704,
24,
985
]
],
[
[
1166,
25,
1383
],
[
1383,
63,
985
]
],
[
[
1166,
62,
752
],
[
752,
24,
985
]
],
[
[
1166,
25,
843
],
[
843,
25,
985
]
]
] | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
],
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
]
] | Dolasetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dolasetron may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dolasetron may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dolasetron may lead to a major life threatening interaction when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Dolasetron may lead to a major life threatening interaction when taken with Tetrabenazine and Tetrabenazine may lead to a major life threatening interaction when taken with Osimertinib |
DB00197 | DB00477 | 1,324 | 216 | [
"DDInter1881",
"DDInter363"
] | Troglitazone | Chlorpromazine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Moderate | 1 | [
[
[
1324,
24,
216
]
],
[
[
1324,
24,
1178
],
[
1178,
1,
216
]
],
[
[
1324,
24,
902
],
[
902,
40,
216
]
],
[
[
1324,
24,
417
],
[
417,
23,
216
]
],
[
[
1324,
24,
927
],
[
927,
63,
216
]
],
[
[
1324,
24,
1466
],
[
1466,
24,
216
]
],
[
[
1324,
63,
521
],
[
521,
24,
216
]
],
[
[
1324,
24,
877
],
[
877,
64,
216
]
],
[
[
1324,
24,
401
],
[
401,
74,
216
]
],
[
[
1324,
24,
1178
],
[
1178,
1,
1321
],
[
1321,
40,
216
]
]
] | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
"Clobazam",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
]
]
] | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Chlorpromazine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Chlorpromazine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Chlorpromazine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) resembles Chlorpromazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Prochlorperazine (Compound) and Prochlorperazine (Compound) resembles Chlorpromazine (Compound) |
DB01045 | DB01211 | 463 | 609 | [
"DDInter1590",
"DDInter393"
] | Rifampicin | Clarithromycin | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Moderate | 1 | [
[
[
463,
24,
609
]
],
[
[
463,
6,
4973
],
[
4973,
45,
609
]
],
[
[
463,
6,
8155
],
[
8155,
46,
609
]
],
[
[
463,
64,
600
],
[
600,
23,
609
]
],
[
[
463,
62,
1101
],
[
1101,
23,
609
]
],
[
[
463,
63,
112
],
[
112,
23,
609
]
],
[
[
463,
24,
568
],
[
568,
24,
609
]
],
[
[
463,
64,
1096
],
[
1096,
24,
609
]
],
[
[
463,
23,
1228
],
[
1228,
63,
609
]
],
[
[
463,
24,
101
],
[
101,
63,
609
]
]
] | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"ABCC5"
],
[
"ABCC5",
"{u} (Gene) is upregulated by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
],
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
]
] | Rifampicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Rifampicin (Compound) binds ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Clarithromycin (Compound)
Rifampicin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin and Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Rifampicin may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB00619 | DB00777 | 1,419 | 146 | [
"DDInter909",
"DDInter1537"
] | Imatinib | Propiomazine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. | Moderate | 1 | [
[
[
1419,
24,
146
]
],
[
[
1419,
63,
508
],
[
508,
1,
146
]
],
[
[
1419,
24,
401
],
[
401,
63,
146
]
],
[
[
1419,
24,
1178
],
[
1178,
1,
146
]
],
[
[
1419,
25,
684
],
[
684,
1,
146
]
],
[
[
1419,
25,
1301
],
[
1301,
40,
146
]
],
[
[
1419,
24,
104
],
[
104,
40,
146
]
],
[
[
1419,
63,
506
],
[
506,
24,
146
]
],
[
[
1419,
23,
222
],
[
222,
63,
146
]
],
[
[
1419,
24,
1144
],
[
1144,
24,
146
]
]
] | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
]
] | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Propiomazine (Compound)
Imatinib may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Propiomazine (Compound)
Imatinib may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Propiomazine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Propiomazine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Imatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine |
DB10315 | DB15091 | 1,137 | 676 | [
"DDInter1127",
"DDInter1901"
] | Measles virus vaccine live attenuated | Upadacitinib | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
1137,
25,
676
]
],
[
[
1137,
64,
1184
],
[
1184,
25,
676
]
],
[
[
1137,
25,
76
],
[
76,
25,
676
]
],
[
[
1137,
63,
617
],
[
617,
25,
676
]
],
[
[
1137,
64,
1184
],
[
1184,
23,
1193
],
[
1193,
23,
676
]
],
[
[
1137,
25,
76
],
[
76,
62,
1193
],
[
1193,
23,
676
]
],
[
[
1137,
64,
869
],
[
869,
63,
1461
],
[
1461,
23,
676
]
],
[
[
1137,
64,
1250
],
[
1250,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1137,
25,
1476
],
[
1476,
63,
1430
],
[
1430,
24,
676
]
],
[
[
1137,
64,
1362
],
[
1362,
63,
1430
],
[
1430,
24,
676
]
]
] | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
],
[
"Mogamulizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
],
[
"Mogamulizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
]
] | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Mogamulizumab and Mogamulizumab may lead to a major life threatening interaction when taken with Upadacitinib
Measles virus vaccine live attenuated may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may lead to a major life threatening interaction when taken with Upadacitinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Mogamulizumab and Mogamulizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib |
DB00390 | DB04868 | 1,252 | 478 | [
"DDInter554",
"DDInter1293"
] | Digoxin | Nilotinib | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
1252,
24,
478
]
],
[
[
1252,
24,
1468
],
[
1468,
63,
478
]
],
[
[
1252,
6,
4973
],
[
4973,
45,
478
]
],
[
[
1252,
7,
1933
],
[
1933,
46,
478
]
],
[
[
1252,
18,
15515
],
[
15515,
46,
478
]
],
[
[
1252,
18,
3229
],
[
3229,
57,
478
]
],
[
[
1252,
21,
28963
],
[
28963,
60,
478
]
],
[
[
1252,
24,
1486
],
[
1486,
24,
478
]
],
[
[
1252,
23,
1384
],
[
1384,
63,
478
]
],
[
[
1252,
23,
752
],
[
752,
24,
478
]
]
] | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Digoxin",
"{u} (Compound) upregulates {v} (Gene)",
"TNFAIP3"
],
[
"TNFAIP3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"ADO"
],
[
"ADO",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"BNIP3"
],
[
"BNIP3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
]
] | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Digoxin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Digoxin (Compound) upregulates TNFAIP3 (Gene) and TNFAIP3 (Gene) is upregulated by Nilotinib (Compound)
Digoxin (Compound) downregulates ADO (Gene) and ADO (Gene) is upregulated by Nilotinib (Compound)
Digoxin (Compound) downregulates BNIP3 (Gene) and BNIP3 (Gene) is downregulated by Nilotinib (Compound)
Digoxin (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Digoxin may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Digoxin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB00501 | DB01036 | 752 | 211 | [
"DDInter380",
"DDInter1832"
] | Cimetidine | Tolterodine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Moderate | 1 | [
[
[
752,
24,
211
]
],
[
[
752,
24,
573
],
[
573,
40,
211
]
],
[
[
752,
62,
494
],
[
494,
40,
211
]
],
[
[
752,
63,
847
],
[
847,
40,
211
]
],
[
[
752,
6,
10215
],
[
10215,
45,
211
]
],
[
[
752,
21,
28893
],
[
28893,
60,
211
]
],
[
[
752,
25,
1493
],
[
1493,
62,
211
]
],
[
[
752,
63,
1018
],
[
1018,
23,
211
]
],
[
[
752,
24,
1045
],
[
1045,
62,
211
]
],
[
[
752,
23,
1387
],
[
1387,
23,
211
]
]
] | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
],
[
"Fesoterodine",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Tolterodine"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Hallucination"
],
[
"Hallucination",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolterodine"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
],
[
"Dacomitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
],
[
"Terbinafine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
]
]
] | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine and Fesoterodine (Compound) resembles Tolterodine (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Disopyramide and Disopyramide (Compound) resembles Tolterodine (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Tolterodine (Compound)
Cimetidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolterodine (Compound)
Cimetidine (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Tolterodine (Compound)
Cimetidine may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib and Dacomitinib may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Terbinafine and Terbinafine may cause a minor interaction that can limit clinical effects when taken with Tolterodine |
DB01233 | DB15066 | 1,311 | 445 | [
"DDInter1197",
"DDInter821"
] | Metoclopramide | Givosiran | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders. | Moderate | 1 | [
[
[
1311,
24,
445
]
],
[
[
1311,
63,
1039
],
[
1039,
24,
445
]
],
[
[
1311,
64,
401
],
[
401,
24,
445
]
],
[
[
1311,
24,
1670
],
[
1670,
25,
445
]
],
[
[
1311,
63,
629
],
[
629,
25,
445
]
],
[
[
1311,
25,
497
],
[
497,
25,
445
]
],
[
[
1311,
63,
1039
],
[
1039,
24,
123
],
[
123,
24,
445
]
],
[
[
1311,
63,
1532
],
[
1532,
63,
1555
],
[
1555,
24,
445
]
],
[
[
1311,
63,
506
],
[
506,
25,
1039
],
[
1039,
24,
445
]
],
[
[
1311,
64,
401
],
[
401,
63,
1555
],
[
1555,
24,
445
]
]
] | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
]
] | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Metoclopramide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Givosiran
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Givosiran
Metoclopramide may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Givosiran
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Metoclopramide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran |
DB08826 | DB08889 | 1,292 | 350 | [
"DDInter489",
"DDInter299"
] | Deferiprone | Carfilzomib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy. | Major | 2 | [
[
[
1292,
25,
350
]
],
[
[
1292,
21,
28762
],
[
28762,
60,
350
]
],
[
[
1292,
25,
1060
],
[
1060,
63,
350
]
],
[
[
1292,
64,
482
],
[
482,
24,
350
]
],
[
[
1292,
25,
1593
],
[
1593,
24,
350
]
],
[
[
1292,
63,
45
],
[
45,
24,
350
]
],
[
[
1292,
64,
581
],
[
581,
25,
350
]
],
[
[
1292,
25,
1510
],
[
1510,
25,
350
]
],
[
[
1292,
25,
1259
],
[
1259,
64,
350
]
],
[
[
1292,
63,
72
],
[
72,
25,
350
]
]
] | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Deferiprone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carfilzomib"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
],
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
]
] | Deferiprone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Deferiprone may lead to a major life threatening interaction when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Deferiprone may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Deferiprone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Deferiprone may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Carfilzomib
Deferiprone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Carfilzomib
Deferiprone may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Carfilzomib
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may lead to a major life threatening interaction when taken with Carfilzomib |
DB01149 | DB06691 | 851 | 849 | [
"DDInter1274",
"DDInter1155"
] | Nefazodone | Mepyramine | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
851,
24,
849
]
],
[
[
851,
63,
1594
],
[
1594,
24,
849
]
],
[
[
851,
6,
12523
],
[
12523,
45,
849
]
],
[
[
851,
24,
412
],
[
412,
63,
849
]
],
[
[
851,
40,
1630
],
[
1630,
24,
849
]
],
[
[
851,
24,
1532
],
[
1532,
24,
849
]
],
[
[
851,
1,
827
],
[
827,
24,
849
]
],
[
[
851,
64,
506
],
[
506,
24,
849
]
],
[
[
851,
25,
1053
],
[
1053,
24,
849
]
],
[
[
851,
63,
662
],
[
662,
35,
849
]
]
] | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nefazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
],
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Trazodone"
],
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
]
] | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nefazodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nefazodone (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nefazodone (Compound) resembles Trazodone (Compound) and Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nefazodone may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nefazodone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine |
DB00398 | DB00697 | 79 | 876 | [
"DDInter1702",
"DDInter1821"
] | Sorafenib | Tizanidine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label]. | Moderate | 1 | [
[
[
79,
24,
876
]
],
[
[
79,
6,
7950
],
[
7950,
45,
876
]
],
[
[
79,
18,
6718
],
[
6718,
57,
876
]
],
[
[
79,
7,
8386
],
[
8386,
57,
876
]
],
[
[
79,
21,
28882
],
[
28882,
60,
876
]
],
[
[
79,
23,
112
],
[
112,
62,
876
]
],
[
[
79,
24,
401
],
[
401,
63,
876
]
],
[
[
79,
63,
912
],
[
912,
24,
876
]
],
[
[
79,
24,
663
],
[
663,
24,
876
]
],
[
[
79,
25,
985
],
[
985,
63,
876
]
]
] | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Sorafenib",
"{u} (Compound) downregulates {v} (Gene)",
"USP22"
],
[
"USP22",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Sorafenib",
"{u} (Compound) upregulates {v} (Gene)",
"MTHFD2"
],
[
"MTHFD2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Sorafenib",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tizanidine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
]
] | Sorafenib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Sorafenib (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Tizanidine (Compound)
Sorafenib (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Tizanidine (Compound)
Sorafenib (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Tizanidine (Compound)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tizanidine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Sorafenib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine |
DB05316 | DB06176 | 749 | 1,342 | [
"DDInter1467",
"DDInter1616"
] | Pimavanserin | Romidepsin | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
749,
24,
1342
]
],
[
[
749,
62,
112
],
[
112,
23,
1342
]
],
[
[
749,
63,
485
],
[
485,
24,
1342
]
],
[
[
749,
24,
1616
],
[
1616,
63,
1342
]
],
[
[
749,
64,
609
],
[
609,
24,
1342
]
],
[
[
749,
25,
384
],
[
384,
63,
1342
]
],
[
[
749,
24,
1374
],
[
1374,
24,
1342
]
],
[
[
749,
64,
1493
],
[
1493,
25,
1342
]
],
[
[
749,
25,
985
],
[
985,
64,
1342
]
],
[
[
749,
24,
351
],
[
351,
64,
1342
]
]
] | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Romidepsin"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
]
] | Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Pimavanserin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Pimavanserin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Pimavanserin may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Romidepsin
Pimavanserin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Romidepsin
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Romidepsin |
DB00794 | DB06228 | 759 | 792 | [
"DDInter1521",
"DDInter1609"
] | Primidone | Rivaroxaban | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Major | 2 | [
[
[
759,
25,
792
]
],
[
[
759,
6,
8374
],
[
8374,
45,
792
]
],
[
[
759,
21,
28847
],
[
28847,
60,
792
]
],
[
[
759,
62,
752
],
[
752,
24,
792
]
],
[
[
759,
24,
1303
],
[
1303,
63,
792
]
],
[
[
759,
63,
79
],
[
79,
24,
792
]
],
[
[
759,
25,
466
],
[
466,
63,
792
]
],
[
[
759,
24,
1683
],
[
1683,
24,
792
]
],
[
[
759,
25,
1151
],
[
1151,
24,
792
]
],
[
[
759,
64,
1419
],
[
1419,
24,
792
]
]
] | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Primidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rivaroxaban"
]
],
[
[
"Primidone",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rivaroxaban"
]
],
[
[
"Primidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
],
[
"Guselkumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
]
] | Primidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rivaroxaban (Compound)
Primidone (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Rivaroxaban (Compound)
Primidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab and Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Primidone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Primidone may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Primidone may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban |
DB01576 | DB09241 | 93 | 1,629 | [
"DDInter526",
"DDInter1186"
] | Dextroamphetamine | Methylene blue | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. | Major | 2 | [
[
[
93,
25,
1629
]
],
[
[
93,
63,
1148
],
[
1148,
24,
1629
]
],
[
[
93,
24,
659
],
[
659,
24,
1629
]
],
[
[
93,
40,
73
],
[
73,
25,
1629
]
],
[
[
93,
74,
1445
],
[
1445,
25,
1629
]
],
[
[
93,
63,
1636
],
[
1636,
25,
1629
]
],
[
[
93,
24,
468
],
[
468,
25,
1629
]
],
[
[
93,
1,
280
],
[
280,
25,
1629
]
],
[
[
93,
64,
593
],
[
593,
25,
1629
]
],
[
[
93,
37,
247
],
[
247,
25,
1629
]
]
] | [
[
[
"Dextroamphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Dextroamphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Dextroamphetamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
],
[
"Isometheptene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Dextroamphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Mephentermine"
],
[
"Mephentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Dextroamphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
]
] | Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Dextroamphetamine (Compound) resembles Phentermine (Compound) and Phentermine may lead to a major life threatening interaction when taken with Methylene blue
Dextroamphetamine (Compound) resembles Pseudoephedrine (Compound) and Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may lead to a major life threatening interaction when taken with Methylene blue
Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may lead to a major life threatening interaction when taken with Methylene blue
Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene and Isometheptene may lead to a major life threatening interaction when taken with Methylene blue
Dextroamphetamine (Compound) resembles Mephentermine (Compound) and Mephentermine may lead to a major life threatening interaction when taken with Methylene blue
Dextroamphetamine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Methylene blue
Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Dextroamphetamine may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Methylene blue |
DB01246 | DB12245 | 820 | 823 | [
"DDInter45",
"DDInter1863"
] | Alimemazine | Triclabendazole | A phenothiazine derivative that is used as an antipruritic. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Moderate | 1 | [
[
[
820,
24,
823
]
],
[
[
820,
62,
1247
],
[
1247,
23,
823
]
],
[
[
820,
24,
1612
],
[
1612,
24,
823
]
],
[
[
820,
63,
1010
],
[
1010,
24,
823
]
],
[
[
820,
24,
1619
],
[
1619,
63,
823
]
],
[
[
820,
25,
843
],
[
843,
24,
823
]
],
[
[
820,
40,
9
],
[
9,
24,
823
]
],
[
[
820,
64,
675
],
[
675,
24,
823
]
],
[
[
820,
74,
1178
],
[
1178,
24,
823
]
],
[
[
820,
23,
286
],
[
286,
24,
823
]
]
] | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
]
] | Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Alimemazine may lead to a major life threatening interaction when taken with Tetrabenazine and Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Alimemazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Alimemazine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Alimemazine (Compound) resembles Trifluoperazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole |
DB00655 | DB01211 | 559 | 609 | [
"DDInter682",
"DDInter393"
] | Estrone | Clarithromycin | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Moderate | 1 | [
[
[
559,
24,
609
]
],
[
[
559,
6,
4973
],
[
4973,
45,
609
]
],
[
[
559,
18,
10375
],
[
10375,
57,
609
]
],
[
[
559,
21,
29180
],
[
29180,
60,
609
]
],
[
[
559,
63,
600
],
[
600,
23,
609
]
],
[
[
559,
62,
752
],
[
752,
23,
609
]
],
[
[
559,
25,
770
],
[
770,
24,
609
]
],
[
[
559,
24,
52
],
[
52,
63,
609
]
],
[
[
559,
24,
1144
],
[
1144,
24,
609
]
],
[
[
559,
63,
1179
],
[
1179,
24,
609
]
]
] | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Estrone",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Estrone",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal distension"
],
[
"Abdominal distension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Estrone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Estrone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
]
] | Estrone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Estrone (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Clarithromycin (Compound)
Estrone (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Clarithromycin (Compound)
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Estrone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Estrone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB00313 | DB00902 | 556 | 104 | [
"DDInter1913",
"DDInter1168"
] | Valproic acid | Methdilazine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene. Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
556,
24,
104
]
],
[
[
556,
24,
13
],
[
13,
24,
104
]
],
[
[
556,
24,
820
],
[
820,
1,
104
]
],
[
[
556,
24,
537
],
[
537,
40,
104
]
],
[
[
556,
24,
401
],
[
401,
63,
104
]
],
[
[
556,
23,
286
],
[
286,
62,
104
]
],
[
[
556,
63,
475
],
[
475,
24,
104
]
],
[
[
556,
23,
1411
],
[
1411,
63,
104
]
],
[
[
556,
24,
593
],
[
593,
64,
104
]
],
[
[
556,
24,
13
],
[
13,
40,
11286
],
[
11286,
1,
104
]
]
] | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methdilazine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound)",
"Diphenylpyraline"
],
[
"Diphenylpyraline",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
]
] | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Methdilazine (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Methdilazine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Methdilazine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Methdilazine (Compound) |
DB01175 | DB08881 | 318 | 868 | [
"DDInter672",
"DDInter1925"
] | Escitalopram | Vemurafenib | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Major | 2 | [
[
[
318,
25,
868
]
],
[
[
318,
6,
8374
],
[
8374,
45,
868
]
],
[
[
318,
18,
5587
],
[
5587,
57,
868
]
],
[
[
318,
21,
29015
],
[
29015,
60,
868
]
],
[
[
318,
62,
112
],
[
112,
23,
868
]
],
[
[
318,
24,
578
],
[
578,
24,
868
]
],
[
[
318,
63,
480
],
[
480,
24,
868
]
],
[
[
318,
23,
760
],
[
760,
63,
868
]
],
[
[
318,
25,
1039
],
[
1039,
24,
868
]
],
[
[
318,
24,
286
],
[
286,
63,
868
]
]
] | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Escitalopram",
"{u} (Compound) downregulates {v} (Gene)",
"SCAND1"
],
[
"SCAND1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Escitalopram",
"{u} (Compound) causes {v} (Side Effect)",
"Eosinophilia"
],
[
"Eosinophilia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
]
] | Escitalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Escitalopram (Compound) downregulates SCAND1 (Gene) and SCAND1 (Gene) is downregulated by Vemurafenib (Compound)
Escitalopram (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Escitalopram may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib |
DB00377 | DB00477 | 1,494 | 216 | [
"DDInter1382",
"DDInter363"
] | Palonosetron | Chlorpromazine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Moderate | 1 | [
[
[
1494,
24,
216
]
],
[
[
1494,
24,
1178
],
[
1178,
1,
216
]
],
[
[
1494,
25,
684
],
[
684,
40,
216
]
],
[
[
1494,
24,
508
],
[
508,
40,
216
]
],
[
[
1494,
25,
1164
],
[
1164,
1,
216
]
],
[
[
1494,
6,
7950
],
[
7950,
45,
216
]
],
[
[
1494,
21,
28751
],
[
28751,
60,
216
]
],
[
[
1494,
23,
112
],
[
112,
62,
216
]
],
[
[
1494,
24,
927
],
[
927,
63,
216
]
],
[
[
1494,
63,
521
],
[
521,
24,
216
]
]
] | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Chlorpromazine"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Chlorpromazine"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
]
] | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Chlorpromazine (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Chlorpromazine (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Trimipramine and Trimipramine (Compound) resembles Chlorpromazine (Compound)
Palonosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Chlorpromazine (Compound)
Palonosetron (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Chlorpromazine (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Chlorpromazine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine |
DB00708 | DB12267 | 1,454 | 1,476 | [
"DDInter1718",
"DDInter233"
] | Sufentanil | Brigatinib | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately. The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018. This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
1454,
24,
1476
]
],
[
[
1454,
24,
629
],
[
629,
24,
1476
]
],
[
[
1454,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
1454,
1,
704
],
[
704,
24,
1476
]
],
[
[
1454,
25,
1133
],
[
1133,
24,
1476
]
],
[
[
1454,
24,
982
],
[
982,
63,
1476
]
],
[
[
1454,
63,
1057
],
[
1057,
25,
1476
]
],
[
[
1454,
24,
384
],
[
384,
25,
1476
]
],
[
[
1454,
24,
629
],
[
629,
24,
1206
],
[
1206,
23,
1476
]
],
[
[
1454,
63,
1184
],
[
1184,
24,
168
],
[
168,
23,
1476
]
]
] | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sufentanil",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sufentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
],
[
"Gemfibrozil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
]
] | Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sufentanil (Compound) resembles Fentanyl (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sufentanil may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Brigatinib
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Brigatinib
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib |
DB00059 | DB00744 | 1,560 | 1,288 | [
"DDInter1404",
"DDInter1962"
] | Pegaspargase | Zileuton | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market. | Moderate | 1 | [
[
[
1560,
24,
1288
]
],
[
[
1560,
24,
482
],
[
482,
24,
1288
]
],
[
[
1560,
24,
187
],
[
187,
63,
1288
]
],
[
[
1560,
25,
1510
],
[
1510,
64,
1288
]
],
[
[
1560,
24,
482
],
[
482,
21,
28826
],
[
28826,
60,
1288
]
],
[
[
1560,
24,
187
],
[
187,
25,
1297
],
[
1297,
63,
1288
]
],
[
[
1560,
24,
912
],
[
912,
24,
482
],
[
482,
24,
1288
]
],
[
[
1560,
24,
1324
],
[
1324,
24,
1297
],
[
1297,
63,
1288
]
],
[
[
1560,
24,
850
],
[
850,
63,
482
],
[
482,
24,
1288
]
],
[
[
1560,
24,
868
],
[
868,
6,
8374
],
[
8374,
45,
1288
]
]
] | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
],
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zileuton"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zileuton"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
],
[
"Pirfenidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Zileuton"
]
]
] | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Pegaspargase may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Zileuton
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Zileuton (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zileuton (Compound) |
DB00059 | DB00758 | 1,560 | 1,347 | [
"DDInter1404",
"DDInter413"
] | Pegaspargase | Clopidogrel | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997. | Moderate | 1 | [
[
[
1560,
24,
1347
]
],
[
[
1560,
24,
1018
],
[
1018,
25,
1347
]
],
[
[
1560,
24,
671
],
[
671,
62,
1347
]
],
[
[
1560,
24,
245
],
[
245,
23,
1347
]
],
[
[
1560,
24,
1338
],
[
1338,
63,
1347
]
],
[
[
1560,
24,
1512
],
[
1512,
24,
1347
]
],
[
[
1560,
24,
802
],
[
802,
64,
1347
]
],
[
[
1560,
24,
256
],
[
256,
75,
1347
]
],
[
[
1560,
24,
1018
],
[
1018,
6,
17955
],
[
17955,
45,
1347
]
],
[
[
1560,
24,
651
],
[
651,
63,
1018
],
[
1018,
25,
1347
]
]
] | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
],
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
],
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"P2RY12"
],
[
"P2RY12",
"{u} (Gene) is bound by {v} (Compound)",
"Clopidogrel"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
]
]
] | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Clopidogrel
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Clopidogrel
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Clopidogrel
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel (Compound) resembles Clopidogrel (Compound) and Prasugrel may lead to a major life threatening interaction when taken with Clopidogrel
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine (Compound) binds P2RY12 (Gene) and P2RY12 (Gene) is bound by Clopidogrel (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel |
DB00604 | DB01115 | 1,425 | 336 | [
"DDInter385",
"DDInter1291"
] | Cisapride | Nifedipine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Major | 2 | [
[
[
1425,
25,
336
]
],
[
[
1425,
6,
7950
],
[
7950,
45,
336
]
],
[
[
1425,
24,
578
],
[
578,
62,
336
]
],
[
[
1425,
23,
1194
],
[
1194,
23,
336
]
],
[
[
1425,
25,
1342
],
[
1342,
63,
336
]
],
[
[
1425,
64,
752
],
[
752,
24,
336
]
],
[
[
1425,
24,
1040
],
[
1040,
63,
336
]
],
[
[
1425,
40,
883
],
[
883,
24,
336
]
],
[
[
1425,
25,
51
],
[
51,
24,
336
]
],
[
[
1425,
24,
467
],
[
467,
24,
336
]
]
] | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nifedipine"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Nifedipine"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nifedipine"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nifedipine"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Cisapride",
"{u} (Compound) resembles {v} (Compound)",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
]
] | Cisapride (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nifedipine (Compound)
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Cisapride may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Cisapride may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Cisapride may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Cisapride (Compound) resembles Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Cisapride may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine |
DB00574 | DB01209 | 121 | 1,359 | [
"DDInter717",
"DDInter531"
] | Fenfluramine | Dezocine | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
121,
24,
1359
]
],
[
[
121,
25,
234
],
[
234,
1,
1359
]
],
[
[
121,
64,
1494
],
[
1494,
24,
1359
]
],
[
[
121,
63,
13
],
[
13,
24,
1359
]
],
[
[
121,
24,
578
],
[
578,
63,
1359
]
],
[
[
121,
24,
1264
],
[
1264,
24,
1359
]
],
[
[
121,
25,
1166
],
[
1166,
24,
1359
]
],
[
[
121,
23,
173
],
[
173,
24,
1359
]
],
[
[
121,
25,
497
],
[
497,
64,
1359
]
],
[
[
121,
25,
593
],
[
593,
25,
1359
]
]
] | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentazocine"
],
[
"Pentazocine",
"{u} (Compound) resembles {v} (Compound)",
"Dezocine"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Fenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxone"
],
[
"Naloxone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dezocine"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dezocine"
]
]
] | Fenfluramine may lead to a major life threatening interaction when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Fenfluramine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Naloxone and Naloxone may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Fenfluramine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Dezocine
Fenfluramine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Dezocine |
DB00741 | DB09381 | 167 | 192 | [
"DDInter885",
"DDInter678"
] | Hydrocortisone | Esterified estrogens | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the vagina. It is being also for the prevention and treatment of osteoporosis. | Moderate | 1 | [
[
[
167,
24,
192
]
],
[
[
167,
23,
771
],
[
771,
62,
192
]
],
[
[
167,
24,
5
],
[
5,
24,
192
]
],
[
[
167,
63,
1685
],
[
1685,
24,
192
]
],
[
[
167,
24,
913
],
[
913,
63,
192
]
],
[
[
167,
1,
617
],
[
617,
24,
192
]
],
[
[
167,
40,
870
],
[
870,
24,
192
]
],
[
[
167,
25,
770
],
[
770,
25,
192
]
],
[
[
167,
23,
771
],
[
771,
62,
617
],
[
617,
24,
192
]
],
[
[
167,
24,
5
],
[
5,
24,
1019
],
[
1019,
63,
192
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
]
] | Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Hydrocortisone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Hydrocortisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Esterified estrogens
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens |
DB00787 | DB01320 | 387 | 651 | [
"DDInter25",
"DDInter783"
] | Acyclovir | Fosphenytoin | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old. Acyclovir was granted FDA approval on 29 March 1982. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Moderate | 1 | [
[
[
387,
24,
651
]
],
[
[
387,
63,
362
],
[
362,
1,
651
]
],
[
[
387,
21,
29028
],
[
29028,
60,
651
]
],
[
[
387,
23,
1096
],
[
1096,
23,
651
]
],
[
[
387,
62,
1031
],
[
1031,
24,
651
]
],
[
[
387,
63,
372
],
[
372,
24,
651
]
],
[
[
387,
24,
50
],
[
50,
24,
651
]
],
[
[
387,
25,
629
],
[
629,
25,
651
]
],
[
[
387,
63,
362
],
[
362,
40,
307
],
[
307,
1,
651
]
],
[
[
387,
21,
29028
],
[
29028,
60,
362
],
[
362,
1,
651
]
]
] | [
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Acyclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Encephalopathy"
],
[
"Encephalopathy",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Acyclovir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acyclovir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acyclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Acyclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Encephalopathy"
],
[
"Encephalopathy",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
]
] | Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Acyclovir (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Fosphenytoin (Compound)
Acyclovir may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Fosphenytoin
Acyclovir may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Acyclovir may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Fosphenytoin
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compound) and Modafinil (Compound) resembles Fosphenytoin (Compound)
Acyclovir (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Phenytoin (Compound) and Phenytoin (Compound) resembles Fosphenytoin (Compound) |
DB00848 | DB11003 | 281 | 748 | [
"DDInter1044",
"DDInter100"
] | Levamisole | Anthrax vaccine | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis. Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. This drug has also been used in combination with other drugs for the treatment of various cancers. [A178117, A178123] Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranul | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
281,
24,
748
]
],
[
[
281,
25,
676
],
[
676,
63,
748
]
],
[
[
281,
24,
1683
],
[
1683,
24,
748
]
],
[
[
281,
64,
1057
],
[
1057,
24,
748
]
],
[
[
281,
24,
270
],
[
270,
63,
748
]
],
[
[
281,
25,
1011
],
[
1011,
24,
748
]
],
[
[
281,
63,
599
],
[
599,
24,
748
]
],
[
[
281,
25,
676
],
[
676,
64,
322
],
[
322,
24,
748
]
],
[
[
281,
24,
1683
],
[
1683,
63,
322
],
[
322,
24,
748
]
],
[
[
281,
64,
1057
],
[
1057,
25,
322
],
[
322,
24,
748
]
]
] | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
]
] | Levamisole may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Levamisole may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Levamisole may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Levamisole may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Levamisole may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB00514 | DB00996 | 506 | 1,198 | [
"DDInter527",
"DDInter791"
] | Dextromethorphan | Gabapentin | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic pain.[A14097,A186179] Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.[A186143,A185981,L8717]. It is structurally and functionally related to another GABA derivative, [pregabalin]. | Moderate | 1 | [
[
[
506,
24,
1198
]
],
[
[
506,
7,
5727
],
[
5727,
46,
1198
]
],
[
[
506,
10,
11594
],
[
11594,
49,
1198
]
],
[
[
506,
21,
28676
],
[
28676,
60,
1198
]
],
[
[
506,
63,
752
],
[
752,
23,
1198
]
],
[
[
506,
24,
1311
],
[
1311,
63,
1198
]
],
[
[
506,
63,
530
],
[
530,
24,
1198
]
],
[
[
506,
24,
717
],
[
717,
24,
1198
]
],
[
[
506,
25,
222
],
[
222,
63,
1198
]
],
[
[
506,
63,
475
],
[
475,
25,
1198
]
]
] | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) upregulates {v} (Gene)",
"AGR2"
],
[
"AGR2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Gabapentin"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) palliates {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) is palliated by {v} (Compound)",
"Gabapentin"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) causes {v} (Side Effect)",
"Nervousness"
],
[
"Nervousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gabapentin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gabapentin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
],
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gabapentin"
]
]
] | Dextromethorphan (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Gabapentin (Compound)
Dextromethorphan (Compound) palliates multiple sclerosis (Disease) and multiple sclerosis (Disease) is palliated by Gabapentin (Compound)
Dextromethorphan (Compound) causes Nervousness (Side Effect) and Nervousness (Side Effect) is caused by Gabapentin (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Gabapentin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Dextromethorphan may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Gabapentin |
DB00041 | DB11601 | 1,648 | 1,270 | [
"DDInter38",
"DDInter1889"
] | Aldesleukin | Tuberculin purified protein derivative | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
1648,
24,
1270
]
],
[
[
1648,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1648,
25,
1064
],
[
1064,
24,
1270
]
],
[
[
1648,
25,
1259
],
[
1259,
63,
1270
]
],
[
[
1648,
63,
305
],
[
305,
24,
1270
]
],
[
[
1648,
64,
1057
],
[
1057,
24,
1270
]
],
[
[
1648,
24,
738
],
[
738,
63,
1270
]
],
[
[
1648,
24,
1531
],
[
1531,
24,
350
],
[
350,
24,
1270
]
],
[
[
1648,
25,
1064
],
[
1064,
25,
350
],
[
350,
24,
1270
]
],
[
[
1648,
25,
611
],
[
611,
24,
1531
],
[
1531,
24,
1270
]
]
] | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
],
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Aldesleukin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Aldesleukin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Aldesleukin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Aldesleukin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Aldesleukin may lead to a major life threatening interaction when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00193 | DB01166 | 534 | 477 | [
"DDInter1841",
"DDInter379"
] | Tramadol | Cilostazol | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [dul | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
534,
24,
477
]
],
[
[
534,
6,
8374
],
[
8374,
45,
477
]
],
[
[
534,
7,
3422
],
[
3422,
46,
477
]
],
[
[
534,
18,
7039
],
[
7039,
57,
477
]
],
[
[
534,
21,
28919
],
[
28919,
60,
477
]
],
[
[
534,
23,
112
],
[
112,
23,
477
]
],
[
[
534,
24,
126
],
[
126,
23,
477
]
],
[
[
534,
25,
820
],
[
820,
63,
477
]
],
[
[
534,
24,
888
],
[
888,
24,
477
]
],
[
[
534,
25,
1010
],
[
1010,
24,
477
]
]
] | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Tramadol",
"{u} (Compound) upregulates {v} (Gene)",
"SATB1"
],
[
"SATB1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Tramadol",
"{u} (Compound) downregulates {v} (Gene)",
"TLE1"
],
[
"TLE1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Tramadol",
"{u} (Compound) causes {v} (Side Effect)",
"Arthritis"
],
[
"Arthritis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
]
] | Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Tramadol (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Cilostazol (Compound)
Tramadol (Compound) downregulates TLE1 (Gene) and TLE1 (Gene) is downregulated by Cilostazol (Compound)
Tramadol (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound)
Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Tramadol may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Tramadol may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol |
DB00277 | DB01339 | 1,031 | 728 | [
"DDInter1791",
"DDInter1922"
] | Theophylline | Vecuronium | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. | Moderate | 1 | [
[
[
1031,
24,
728
]
],
[
[
1031,
24,
1610
],
[
1610,
1,
728
]
],
[
[
1031,
24,
1579
],
[
1579,
40,
728
]
],
[
[
1031,
21,
28642
],
[
28642,
60,
728
]
],
[
[
1031,
24,
1194
],
[
1194,
23,
728
]
],
[
[
1031,
24,
1620
],
[
1620,
24,
728
]
],
[
[
1031,
1,
746
],
[
746,
24,
728
]
],
[
[
1031,
63,
964
],
[
964,
24,
728
]
],
[
[
1031,
24,
1610
],
[
1610,
1,
1665
],
[
1665,
1,
728
]
],
[
[
1031,
24,
1579
],
[
1579,
40,
1610
],
[
1610,
1,
728
]
]
] | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
],
[
"Rocuronium",
"{u} (Compound) resembles {v} (Compound)",
"Vecuronium"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
],
[
"Pancuronium",
"{u} (Compound) resembles {v} (Compound)",
"Vecuronium"
]
],
[
[
"Theophylline",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vecuronium"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vecuronium"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]
],
[
[
"Theophylline",
"{u} (Compound) resembles {v} (Compound)",
"Dyphylline"
],
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
],
[
"Rocuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pipecuronium"
],
[
"Pipecuronium",
"{u} (Compound) resembles {v} (Compound)",
"Vecuronium"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
],
[
"Pancuronium",
"{u} (Compound) resembles {v} (Compound)",
"Rocuronium"
],
[
"Rocuronium",
"{u} (Compound) resembles {v} (Compound)",
"Vecuronium"
]
]
] | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Vecuronium (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium (Compound)
Theophylline (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Vecuronium (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Vecuronium
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium
Theophylline (Compound) resembles Dyphylline (Compound) and Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Pipecuronium (Compound) and Pipecuronium (Compound) resembles Vecuronium (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Rocuronium (Compound) and Rocuronium (Compound) resembles Vecuronium (Compound) |
DB04844 | DB11130 | 843 | 407 | [
"DDInter1778",
"DDInter1344"
] | Tetrabenazine | Opium | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
843,
24,
407
]
],
[
[
843,
63,
662
],
[
662,
24,
407
]
],
[
[
843,
64,
104
],
[
104,
24,
407
]
],
[
[
843,
24,
849
],
[
849,
24,
407
]
],
[
[
843,
24,
1609
],
[
1609,
63,
407
]
],
[
[
843,
64,
1053
],
[
1053,
25,
407
]
],
[
[
843,
25,
1629
],
[
1629,
25,
407
]
],
[
[
843,
63,
662
],
[
662,
63,
558
],
[
558,
24,
407
]
],
[
[
843,
64,
104
],
[
104,
24,
409
],
[
409,
24,
407
]
],
[
[
843,
24,
849
],
[
849,
63,
409
],
[
409,
24,
407
]
]
] | [
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
]
] | Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tetrabenazine may lead to a major life threatening interaction when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tetrabenazine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opium
Tetrabenazine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Opium
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tetrabenazine may lead to a major life threatening interaction when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB01367 | DB11186 | 1,163 | 1,609 | [
"DDInter1572",
"DDInter1427"
] | Rasagiline | Pentoxyverine | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed. | Major | 2 | [
[
[
1163,
25,
1609
]
],
[
[
1163,
63,
104
],
[
104,
24,
1609
]
],
[
[
1163,
24,
649
],
[
649,
24,
1609
]
],
[
[
1163,
64,
506
],
[
506,
24,
1609
]
],
[
[
1163,
64,
1053
],
[
1053,
25,
1609
]
],
[
[
1163,
63,
104
],
[
104,
63,
314
],
[
314,
24,
1609
]
],
[
[
1163,
63,
999
],
[
999,
24,
314
],
[
314,
24,
1609
]
],
[
[
1163,
24,
649
],
[
649,
63,
314
],
[
314,
24,
1609
]
],
[
[
1163,
64,
506
],
[
506,
24,
314
],
[
314,
24,
1609
]
],
[
[
1163,
64,
1264
],
[
1264,
63,
314
],
[
314,
24,
1609
]
]
] | [
[
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
]
] | Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Rasagiline may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Rasagiline may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Pentoxyverine
Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Rasagiline may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Rasagiline may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine |
DB00262 | DB08886 | 552 | 637 | [
"DDInter302",
"DDInter126"
] | Carmustine | Asparaginase Erwinia chrysanthemi | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. | Moderate | 1 | [
[
[
552,
24,
637
]
],
[
[
552,
24,
328
],
[
328,
24,
637
]
],
[
[
552,
35,
37
],
[
37,
24,
637
]
],
[
[
552,
24,
1613
],
[
1613,
63,
637
]
],
[
[
552,
63,
912
],
[
912,
24,
637
]
],
[
[
552,
64,
581
],
[
581,
24,
637
]
],
[
[
552,
25,
1510
],
[
1510,
25,
637
]
],
[
[
552,
24,
328
],
[
328,
24,
37
],
[
37,
24,
637
]
],
[
[
552,
35,
37
],
[
37,
63,
328
],
[
328,
24,
637
]
],
[
[
552,
24,
850
],
[
850,
63,
640
],
[
640,
24,
637
]
]
] | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Carmustine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Carmustine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
]
] | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Carmustine (Compound) resembles Lomustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Carmustine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Carmustine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Carmustine (Compound) resembles Lomustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi |
DB00008 | DB00087 | 491 | 599 | [
"DDInter1407",
"DDInter41"
] | Peginterferon alfa-2a | Alemtuzumab | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is much higher than that for MS, and also at more frequent dosing.[L43397, L30335] | Moderate | 1 | [
[
[
491,
24,
599
]
],
[
[
491,
24,
597
],
[
597,
63,
599
]
],
[
[
491,
24,
367
],
[
367,
24,
599
]
],
[
[
491,
25,
1101
],
[
1101,
63,
599
]
],
[
[
491,
63,
1057
],
[
1057,
24,
599
]
],
[
[
491,
23,
450
],
[
450,
63,
599
]
],
[
[
491,
25,
1066
],
[
1066,
64,
599
]
],
[
[
491,
24,
597
],
[
597,
24,
281
],
[
281,
63,
599
]
],
[
[
491,
24,
36
],
[
36,
63,
597
],
[
597,
63,
599
]
],
[
[
491,
25,
1101
],
[
1101,
23,
597
],
[
597,
63,
599
]
]
] | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamisole"
],
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
]
] | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Alemtuzumab
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Levamisole and Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab |
DB00197 | DB12001 | 1,324 | 564 | [
"DDInter1881",
"DDInter7"
] | Troglitazone | Abemaciclib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with . Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. | Moderate | 1 | [
[
[
1324,
24,
564
]
],
[
[
1324,
24,
868
],
[
868,
24,
564
]
],
[
[
1324,
24,
1017
],
[
1017,
63,
564
]
],
[
[
1324,
63,
912
],
[
912,
24,
564
]
],
[
[
1324,
23,
1101
],
[
1101,
24,
564
]
],
[
[
1324,
24,
215
],
[
215,
25,
564
]
],
[
[
1324,
25,
990
],
[
990,
25,
564
]
],
[
[
1324,
24,
868
],
[
868,
63,
536
],
[
536,
24,
564
]
],
[
[
1324,
24,
1335
],
[
1335,
24,
868
],
[
868,
24,
564
]
],
[
[
1324,
63,
912
],
[
912,
24,
868
],
[
868,
24,
564
]
]
] | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
]
] | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may lead to a major life threatening interaction when taken with Abemaciclib
Troglitazone may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Abemaciclib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib |
DB06779 | DB11312 | 365 | 298 | [
"DDInter470",
"DDInter1542"
] | Dalteparin | Protein C | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot formation. The Protein C pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli. A lack of protein C in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation. Protein C is available in concentrated form as the product Ceprotin, which is indicated for use in pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. | Moderate | 1 | [
[
[
365,
24,
298
]
],
[
[
365,
64,
707
],
[
707,
24,
298
]
],
[
[
365,
24,
321
],
[
321,
63,
298
]
],
[
[
365,
25,
235
],
[
235,
24,
298
]
],
[
[
365,
63,
1461
],
[
1461,
24,
298
]
],
[
[
365,
25,
1421
],
[
1421,
63,
298
]
],
[
[
365,
64,
1046
],
[
1046,
25,
298
]
],
[
[
365,
64,
707
],
[
707,
24,
321
],
[
321,
63,
298
]
],
[
[
365,
24,
321
],
[
321,
63,
707
],
[
707,
24,
298
]
],
[
[
365,
64,
500
],
[
500,
25,
707
],
[
707,
24,
298
]
]
] | [
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
],
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Protein C"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
],
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
],
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
]
] | Dalteparin may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Dalteparin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Dalteparin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Dalteparin may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Protein C
Dalteparin may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Dalteparin may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Protein C |
DB00501 | DB01166 | 752 | 477 | [
"DDInter380",
"DDInter379"
] | Cimetidine | Cilostazol | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
752,
24,
477
]
],
[
[
752,
6,
8374
],
[
8374,
45,
477
]
],
[
[
752,
21,
29340
],
[
29340,
60,
477
]
],
[
[
752,
23,
112
],
[
112,
23,
477
]
],
[
[
752,
24,
126
],
[
126,
23,
477
]
],
[
[
752,
24,
655
],
[
655,
63,
477
]
],
[
[
752,
62,
216
],
[
216,
24,
477
]
],
[
[
752,
25,
888
],
[
888,
24,
477
]
],
[
[
752,
63,
109
],
[
109,
24,
477
]
],
[
[
752,
23,
623
],
[
623,
63,
477
]
]
] | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Stevens-Johnson syndrome"
],
[
"Stevens-Johnson syndrome",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
]
] | Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Cimetidine (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Cilostazol (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Cimetidine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quetiapine and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol |
DB00372 | DB01612 | 999 | 1,637 | [
"DDInter1793",
"DDInter92"
] | Thiethylperazine | Amyl Nitrite | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
999,
24,
1637
]
],
[
[
999,
24,
946
],
[
946,
24,
1637
]
],
[
[
999,
24,
180
],
[
180,
63,
1637
]
],
[
[
999,
63,
475
],
[
475,
24,
1637
]
],
[
[
999,
25,
593
],
[
593,
24,
1637
]
],
[
[
999,
25,
843
],
[
843,
63,
1637
]
],
[
[
999,
24,
876
],
[
876,
25,
1637
]
],
[
[
999,
24,
946
],
[
946,
64,
475
],
[
475,
24,
1637
]
],
[
[
999,
24,
413
],
[
413,
63,
475
],
[
475,
24,
1637
]
],
[
[
999,
63,
475
],
[
475,
25,
946
],
[
946,
24,
1637
]
]
] | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
],
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
]
] | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Thiethylperazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Thiethylperazine may lead to a major life threatening interaction when taken with Tetrabenazine and Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Amyl Nitrite
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone and Buspirone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline and Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Buspirone and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite |
DB00451 | DB01125 | 542 | 279 | [
"DDInter1064",
"DDInter98"
] | Levothyroxine | Anisindione | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T<sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or ), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.[F4636,A35722] In response to Thyroid Stimulating Hormone (TSH) release by | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver. | Moderate | 1 | [
[
[
542,
24,
279
]
],
[
[
542,
63,
1647
],
[
1647,
23,
279
]
],
[
[
542,
23,
467
],
[
467,
23,
279
]
],
[
[
542,
24,
913
],
[
913,
63,
279
]
],
[
[
542,
24,
660
],
[
660,
24,
279
]
],
[
[
542,
63,
1645
],
[
1645,
24,
279
]
],
[
[
542,
62,
417
],
[
417,
24,
279
]
],
[
[
542,
23,
752
],
[
752,
24,
279
]
],
[
[
542,
40,
1152
],
[
1152,
24,
279
]
],
[
[
542,
24,
1026
],
[
1026,
25,
279
]
]
] | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anisindione"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anisindione"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
],
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
]
] | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Anisindione
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Anisindione
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Levothyroxine (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone may lead to a major life threatening interaction when taken with Anisindione |
DB00443 | DB01155 | 251 | 872 | [
"DDInter195",
"DDInter813"
] | Betamethasone | Gemifloxacin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. | Major | 2 | [
[
[
251,
25,
872
]
],
[
[
251,
25,
739
],
[
739,
1,
872
]
],
[
[
251,
25,
945
],
[
945,
40,
872
]
],
[
[
251,
64,
1176
],
[
1176,
1,
872
]
],
[
[
251,
21,
29754
],
[
29754,
60,
872
]
],
[
[
251,
24,
589
],
[
589,
23,
872
]
],
[
[
251,
63,
1648
],
[
1648,
23,
872
]
],
[
[
251,
24,
1450
],
[
1450,
63,
872
]
],
[
[
251,
24,
355
],
[
355,
24,
872
]
],
[
[
251,
23,
688
],
[
688,
24,
872
]
]
] | [
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Tendon rupture"
],
[
"Tendon rupture",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gemifloxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
]
]
] | Betamethasone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Betamethasone may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Compound)
Betamethasone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gemifloxacin (Compound)
Betamethasone (Compound) causes Tendon rupture (Side Effect) and Tendon rupture (Side Effect) is caused by Gemifloxacin (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin |
DB00427 | DB00593 | 1,233 | 1,464 | [
"DDInter1879",
"DDInter695"
] | Triprolidine | Ethosuximide | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Moderate | 1 | [
[
[
1233,
24,
1464
]
],
[
[
1233,
24,
401
],
[
401,
63,
1464
]
],
[
[
1233,
24,
1614
],
[
1614,
24,
1464
]
],
[
[
1233,
63,
1594
],
[
1594,
24,
1464
]
],
[
[
1233,
24,
401
],
[
401,
21,
28691
],
[
28691,
60,
1464
]
],
[
[
1233,
24,
832
],
[
832,
24,
401
],
[
401,
63,
1464
]
],
[
[
1233,
24,
1219
],
[
1219,
6,
8374
],
[
8374,
45,
1464
]
],
[
[
1233,
24,
1609
],
[
1609,
63,
401
],
[
401,
63,
1464
]
],
[
[
1233,
63,
1594
],
[
1594,
21,
28681
],
[
28681,
60,
1464
]
],
[
[
1233,
63,
128
],
[
128,
24,
401
],
[
401,
63,
1464
]
]
] | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethosuximide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ethosuximide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethosuximide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
]
] | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Ethosuximide (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ethosuximide (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Ethosuximide (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide |
DB00014 | DB09054 | 521 | 384 | [
"DDInter839",
"DDInter905"
] | Goserelin | Idelalisib | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
521,
24,
384
]
],
[
[
521,
25,
318
],
[
318,
23,
384
]
],
[
[
521,
24,
479
],
[
479,
23,
384
]
],
[
[
521,
25,
1618
],
[
1618,
24,
384
]
],
[
[
521,
24,
1570
],
[
1570,
24,
384
]
],
[
[
521,
24,
1228
],
[
1228,
63,
384
]
],
[
[
521,
23,
1247
],
[
1247,
24,
384
]
],
[
[
521,
24,
594
],
[
594,
25,
384
]
],
[
[
521,
24,
1293
],
[
1293,
64,
384
]
],
[
[
521,
25,
1568
],
[
1568,
25,
384
]
]
] | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
],
[
"Valbenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
]
] | Goserelin may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Goserelin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Idelalisib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine and Valbenazine may lead to a major life threatening interaction when taken with Idelalisib
Goserelin may lead to a major life threatening interaction when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Idelalisib |
DB01159 | DB06589 | 419 | 1,250 | [
"DDInter854",
"DDInter1400"
] | Halothane | Pazopanib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
419,
24,
1250
]
],
[
[
419,
6,
12523
],
[
12523,
45,
1250
]
],
[
[
419,
62,
112
],
[
112,
23,
1250
]
],
[
[
419,
24,
1151
],
[
1151,
24,
1250
]
],
[
[
419,
63,
455
],
[
455,
24,
1250
]
],
[
[
419,
24,
214
],
[
214,
63,
1250
]
],
[
[
419,
64,
11
],
[
11,
25,
1250
]
],
[
[
419,
25,
868
],
[
868,
64,
1250
]
],
[
[
419,
24,
384
],
[
384,
64,
1250
]
],
[
[
419,
24,
477
],
[
477,
25,
1250
]
]
] | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Halothane",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Halothane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
]
] | Halothane (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pazopanib (Compound)
Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Halothane may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Pazopanib
Halothane may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Pazopanib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Pazopanib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Pazopanib |
DB00488 | DB00543 | 196 | 87 | [
"DDInter57",
"DDInter82"
] | Altretamine | Amoxapine | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation. | Moderate | 1 | [
[
[
196,
24,
87
]
],
[
[
196,
64,
695
],
[
695,
40,
87
]
],
[
[
196,
21,
28852
],
[
28852,
60,
87
]
],
[
[
196,
25,
770
],
[
770,
63,
87
]
],
[
[
196,
24,
752
],
[
752,
24,
87
]
],
[
[
196,
24,
1264
],
[
1264,
63,
87
]
],
[
[
196,
25,
1011
],
[
1011,
64,
87
]
],
[
[
196,
64,
695
],
[
695,
40,
1119
],
[
1119,
1,
87
]
],
[
[
196,
21,
28852
],
[
28852,
60,
11372
],
[
11372,
1,
87
]
],
[
[
196,
21,
28658
],
[
28658,
60,
905
],
[
905,
40,
87
]
]
] | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amoxapine"
]
],
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amoxapine"
]
],
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Chlordiazepoxide"
],
[
"Chlordiazepoxide",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lorazepam"
],
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
]
]
] | Altretamine may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Amoxapine (Compound)
Altretamine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Amoxapine (Compound)
Altretamine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Altretamine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Amoxapine
Altretamine may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide (Compound) resembles Amoxapine (Compound)
Altretamine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Zuclopenthixol (Compound) and Zuclopenthixol (Compound) resembles Amoxapine (Compound)
Altretamine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Lorazepam (Compound) and Lorazepam (Compound) resembles Amoxapine (Compound) |
DB01068 | DB12267 | 1,565 | 1,476 | [
"DDInter411",
"DDInter233"
] | Clonazepam | Brigatinib | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
1565,
24,
1476
]
],
[
[
1565,
63,
629
],
[
629,
24,
1476
]
],
[
[
1565,
24,
1531
],
[
1531,
24,
1476
]
],
[
[
1565,
40,
1382
],
[
1382,
24,
1476
]
],
[
[
1565,
64,
475
],
[
475,
24,
1476
]
],
[
[
1565,
24,
1619
],
[
1619,
63,
1476
]
],
[
[
1565,
1,
1418
],
[
1418,
24,
1476
]
],
[
[
1565,
63,
1057
],
[
1057,
25,
1476
]
],
[
[
1565,
24,
129
],
[
129,
25,
1476
]
],
[
[
1565,
24,
283
],
[
283,
64,
1476
]
]
] | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Clonazepam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
],
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
]
] | Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clonazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clonazepam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clonazepam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Brigatinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Brigatinib |
DB06663 | DB14840 | 1,154 | 861 | [
"DDInter1398",
"DDInter1601"
] | Pasireotide | Ripretinib | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors. | Moderate | 1 | [
[
[
1154,
24,
861
]
],
[
[
1154,
25,
351
],
[
351,
24,
861
]
],
[
[
1154,
64,
392
],
[
392,
24,
861
]
],
[
[
1154,
24,
1017
],
[
1017,
24,
861
]
],
[
[
1154,
63,
473
],
[
473,
24,
861
]
],
[
[
1154,
1,
966
],
[
966,
24,
861
]
],
[
[
1154,
24,
384
],
[
384,
25,
861
]
],
[
[
1154,
25,
913
],
[
913,
25,
861
]
],
[
[
1154,
64,
609
],
[
609,
25,
861
]
],
[
[
1154,
25,
351
],
[
351,
24,
214
],
[
214,
24,
861
]
]
] | [
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Pasireotide",
"{u} (Compound) resembles {v} (Compound)",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ripretinib"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ripretinib"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ripretinib"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
]
] | Pasireotide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pasireotide may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pasireotide (Compound) resembles Octreotide (Compound) and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Ripretinib
Pasireotide may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Ripretinib
Pasireotide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ripretinib
Pasireotide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib |
DB00046 | DB01234 | 1,179 | 1,220 | [
"DDInter940",
"DDInter513"
] | Insulin lispro | Dexamethasone | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Moderate | 1 | [
[
[
1179,
24,
1220
]
],
[
[
1179,
24,
870
],
[
870,
1,
1220
]
],
[
[
1179,
24,
175
],
[
175,
40,
1220
]
],
[
[
1179,
23,
1103
],
[
1103,
1,
1220
]
],
[
[
1179,
24,
688
],
[
688,
23,
1220
]
],
[
[
1179,
24,
22
],
[
22,
62,
1220
]
],
[
[
1179,
24,
959
],
[
959,
24,
1220
]
],
[
[
1179,
24,
1687
],
[
1687,
63,
1220
]
],
[
[
1179,
63,
305
],
[
305,
24,
1220
]
],
[
[
1179,
25,
1539
],
[
1539,
25,
1220
]
]
] | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
],
[
"Stanozolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Insulin lispro",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
]
] | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) resembles Dexamethasone (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol and Stanozolol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Insulin lispro may lead to a major life threatening interaction when taken with Ofloxacin and Ofloxacin may lead to a major life threatening interaction when taken with Dexamethasone |
DB00539 | DB12161 | 11 | 730 | [
"DDInter1837",
"DDInter512"
] | Toremifene | Deutetrabenazine | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound . This allows less frequent dosing and a lower daily dose with improvement in tolerability . Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine . Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and neuropsychiatric disturbances that interfere with daily functioning and significantly reduce the quality of life. The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions . Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission . Deutetrabenazine depletes the levels of presynaptic dopamine by blocking VMAT2, which is responsible for the uptake of dopamine into synaptic vesicles in monoaminergic neurons and exocytotic release . As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease . In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo . It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. | Major | 2 | [
[
[
11,
25,
730
]
],
[
[
11,
23,
112
],
[
112,
23,
730
]
],
[
[
11,
64,
322
],
[
322,
24,
730
]
],
[
[
11,
24,
1559
],
[
1559,
24,
730
]
],
[
[
11,
25,
971
],
[
971,
24,
730
]
],
[
[
11,
24,
283
],
[
283,
63,
730
]
],
[
[
11,
36,
888
],
[
888,
24,
730
]
],
[
[
11,
1,
1376
],
[
1376,
24,
730
]
],
[
[
11,
25,
1619
],
[
1619,
63,
730
]
],
[
[
11,
35,
543
],
[
543,
24,
730
]
]
] | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
]
] | Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Toremifene may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Toremifene may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Toremifene (Compound) resembles Tamoxifen (Compound) and Toremifene may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Toremifene (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Toremifene may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Toremifene (Compound) resembles Loperamide (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine |
DB00323 | DB00470 | 1,062 | 530 | [
"DDInter1829",
"DDInter601"
] | Tolcapone | Dronabinol | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function . | Moderate | 1 | [
[
[
1062,
24,
530
]
],
[
[
1062,
24,
1614
],
[
1614,
40,
530
]
],
[
[
1062,
6,
6017
],
[
6017,
45,
530
]
],
[
[
1062,
21,
29226
],
[
29226,
60,
530
]
],
[
[
1062,
63,
701
],
[
701,
24,
530
]
],
[
[
1062,
24,
1219
],
[
1219,
63,
530
]
],
[
[
1062,
24,
1594
],
[
1594,
24,
530
]
],
[
[
1062,
1,
1533
],
[
1533,
63,
530
]
],
[
[
1062,
24,
1614
],
[
1614,
6,
3800
],
[
3800,
45,
530
]
],
[
[
1062,
6,
6017
],
[
6017,
45,
441
],
[
441,
62,
530
]
]
] | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
]
],
[
[
"Tolcapone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Dronabinol"
]
],
[
[
"Tolcapone",
"{u} (Compound) causes {v} (Side Effect)",
"Sinusitis"
],
[
"Sinusitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronabinol"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Tolcapone",
"{u} (Compound) resembles {v} (Compound)",
"Entacapone"
],
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} (Compound) binds {v} (Gene)",
"CNR1"
],
[
"CNR1",
"{u} (Gene) is bound by {v} (Compound)",
"Dronabinol"
]
],
[
[
"Tolcapone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dronabinol"
]
]
] | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Tolcapone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dronabinol (Compound)
Tolcapone (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Dronabinol (Compound)
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Tolcapone (Compound) resembles Entacapone (Compound) and Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) binds CNR1 (Gene) and CNR1 (Gene) is bound by Dronabinol (Compound)
Tolcapone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Delavirdine (Compound) and Delavirdine may cause a minor interaction that can limit clinical effects when taken with Dronabinol |
DB00637 | DB01211 | 1,557 | 609 | [
"DDInter128",
"DDInter393"
] | Astemizole | Clarithromycin | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Major | 2 | [
[
[
1557,
25,
609
]
],
[
[
1557,
63,
1570
],
[
1570,
24,
609
]
],
[
[
1557,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1557,
18,
20003
],
[
20003,
57,
609
]
],
[
[
1557,
7,
8839
],
[
8839,
57,
609
]
],
[
[
1557,
64,
600
],
[
600,
23,
609
]
],
[
[
1557,
63,
1101
],
[
1101,
23,
609
]
],
[
[
1557,
24,
479
],
[
479,
23,
609
]
],
[
[
1557,
23,
1247
],
[
1247,
23,
609
]
],
[
[
1557,
25,
34
],
[
34,
62,
609
]
]
] | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Astemizole",
"{u} (Compound) downregulates {v} (Gene)",
"NOSIP"
],
[
"NOSIP",
"{u} (Gene) is downregulated by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Astemizole",
"{u} (Compound) upregulates {v} (Gene)",
"GNPDA1"
],
[
"GNPDA1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
],
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
]
] | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Astemizole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Astemizole (Compound) downregulates NOSIP (Gene) and NOSIP (Gene) is downregulated by Clarithromycin (Compound)
Astemizole (Compound) upregulates GNPDA1 (Gene) and GNPDA1 (Gene) is downregulated by Clarithromycin (Compound)
Astemizole may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Astemizole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Astemizole may lead to a major life threatening interaction when taken with Fosamprenavir and Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.